<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="ppub"/></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS190173</article-id><article-id pub-id-type="doi">10.1101/2023.10.23.563619</article-id><article-id pub-id-type="archive">PPR747573</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">2</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Platelet proteo-transcriptomic profiling validates mediators of thrombosis and proteostasis in patients with myeloproliferative neoplasms</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kelliher</surname><given-names>Sarah</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A3">3</xref><xref ref-type="aff" rid="A4">4</xref><xref ref-type="fn" rid="FN1">⊕</xref></contrib><contrib contrib-type="author"><name><surname>Gamba</surname><given-names>Sara</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Weiss</surname><given-names>Luisa</given-names></name><xref ref-type="aff" rid="A4">4</xref><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Shen</surname><given-names>Zhu</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Marchetti</surname><given-names>Marina</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Schieppati</surname><given-names>Francesca</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Scaife</surname><given-names>Caitriona</given-names></name><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Madden</surname><given-names>Stephen</given-names></name><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Bennett</surname><given-names>Kathleen</given-names></name><xref ref-type="aff" rid="A9">9</xref></contrib><contrib contrib-type="author"><name><surname>Fortune</surname><given-names>Anne</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Maung</surname><given-names>Su</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Fay</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ní Áinle</surname><given-names>Fionnuala</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref><xref ref-type="aff" rid="A4">4</xref><xref ref-type="aff" rid="A11">11</xref></contrib><contrib contrib-type="author"><name><surname>Maguire</surname><given-names>Patricia</given-names></name><xref ref-type="aff" rid="A4">4</xref><xref ref-type="aff" rid="A6">6</xref><xref ref-type="aff" rid="A12">12</xref></contrib><contrib contrib-type="author"><name><surname>Falanga</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="A5">5</xref><xref ref-type="aff" rid="A13">13</xref></contrib><contrib contrib-type="author"><name><surname>Kevane</surname><given-names>Barry</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref><xref ref-type="aff" rid="A4">4</xref><xref ref-type="fn" rid="FN2">#</xref></contrib><contrib contrib-type="author"><name><surname>Krishnan</surname><given-names>Anandi</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A14">14</xref><xref ref-type="aff" rid="A15">15</xref><xref ref-type="fn" rid="FN2">#</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>School of Medicine, University College Dublin, Dublin, Ireland</aff><aff id="A2"><label>2</label>Stanford University School of Medicine, Stanford University, Stanford, CA, USA</aff><aff id="A3"><label>3</label>Department of Haematology, Mater Misericordiae University Hospital, Dublin, Ireland</aff><aff id="A4"><label>4</label>UCD Conway SPHERE Research Group, University College Dublin, Dublin, Ireland</aff><aff id="A5"><label>5</label>Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy</aff><aff id="A6"><label>6</label>School of Biomolecular and Biomedical Science, University College Dublin, Dublin, Ireland</aff><aff id="A7"><label>7</label>UCD Conway Institute for Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland</aff><aff id="A8"><label>8</label>Data Science Centre, Royal College of Surgeons in Ireland, Dublin, Ireland</aff><aff id="A9"><label>9</label>School of Population Health, RCSI University of Medicine and Health Sciences, Dublin, Ireland</aff><aff id="A10"><label>10</label>Department of Haematology, Rotunda Hospital, Dublin, Ireland</aff><aff id="A11"><label>11</label>School of Medicine, Royal College of Surgeons in Ireland</aff><aff id="A12"><label>12</label>UCD Institute for Discovery, University College Dublin, Dublin, Ireland</aff><aff id="A13"><label>13</label>University of Milano-Bicocca, Department of Medicine and Surgery, Monza, Italy</aff><aff id="A14"><label>14</label>Rutgers University, Piscataway, NJ</aff><aff id="A15"><label>15</label>Stanford Cancer Institute, Stanford, CA, USA</aff><author-notes><corresp id="CR1"><label>*</label><bold>“Corresponding Author:</bold> Anandi Krishnan, PhD Stanford University, Stanford, CA <email>anandi.krishnan@stanford.edu</email></corresp><fn id="FN1"><label>⊕</label><p id="P1">S.K. conducted part of this research as a visiting training fellow with A.K. at Stanford University</p></fn><fn id="FN2"><label>#</label><p id="P2">A.K. and B.K. are co-senior authors</p></fn></author-notes><pub-date pub-type="nihms-submitted"><day>27</day><month>10</month><year>2023</year></pub-date><pub-date pub-type="preprint"><day>26</day><month>10</month><year>2023</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P3">Patients with chronic Myeloproliferative Neoplasms (MPN) including polycythemia vera (PV) and essential thrombocythemia (ET) exhibit unique clinical features, such as a tendency toward thrombosis and hemorrhage, and risk of disease progression to secondary bone marrow fibrosis and/or acute leukemia. Although an increase in blood cell lineage counts (quantitative features) contribute to these morbid sequelae, the significant qualitative abnormalities of myeloid cells that contribute to vascular risk are not well understood. Here, we address this critical knowledge gap via a comprehensive and untargeted profiling of the platelet proteome in a large (n= 140) cohort of patients (from two independent sites) with an established diagnosis of PV and ET (and complement prior work on the MPN platelet transcriptome from a third site). We discover distinct MPN platelet protein expression and confirm key molecular impairments associated with proteostasis and thrombosis mechanisms of potential relevance to MPN pathology. Specifically, we validate expression of high-priority candidate markers from the platelet transcriptome at the platelet proteome (<italic>e.g.,</italic> calreticulin (CALR), Fc gamma receptor (FcγRIIA) and galectin-1 (LGALS1) pointing to their likely significance in the proinflammatory, prothrombotic and profibrotic phenotypes in patients with MPN. Together, our proteo-transcriptomic study identifies the peripherally-derived platelet molecular profile as a potential window into MPN pathophysiology and demonstrates the value of integrative multi-omic approaches in gaining a better understanding of the complex molecular dynamics of disease.</p></abstract></article-meta></front><body><sec id="S1" sec-type="intro"><title>Introduction</title><p id="P4">Myeloproliferative neoplasms (MPN) are chronic bone marrow malignancies characterised by clonal proliferation of hematopoietic precursors and elevated cell counts in peripheral blood. The three most common Philadelphia-chromosome negative (Ph<sup>-</sup>) MPN subtypes polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF), are diagnosed according to morphologic, clinical, laboratory, and genetic criteria<sup><xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R2">2</xref></sup>. Patients with MPN are at risk of progression to secondary bone marrow fibrosis or acute leukemia and experience a substantial burden of microvascular symptoms, negatively impacting their quality of life<sup><xref ref-type="bibr" rid="R3">3</xref>–<xref ref-type="bibr" rid="R5">5</xref></sup>. However, it is thrombosis, including both arterial and venous events, which represents the leading cause of morbidity and mortality for patients with PV and ET<sup><xref ref-type="bibr" rid="R6">6</xref>–<xref ref-type="bibr" rid="R9">9</xref></sup>. Several patient and disease-specific characteristics have been shown to correlate with increased clinical risk, yet despite currently available standard of care, the prediction and prevention of disease complications remains challenging<sup><xref ref-type="bibr" rid="R10">10</xref></sup>.</p><p id="P5">The discovery of the <italic>JAK2</italic> V617F mutation in 2005 heralded a new era in the management of MPN, and the application of genomic techniques has radically modified diagnostic and prognostic approaches in the interim<sup><xref ref-type="bibr" rid="R11">11</xref></sup>. In addition to the MPN driver mutations (<italic>JAK2</italic> V617F, <italic>CALR, MPL</italic> &amp; <italic>JAK2</italic> exon 12) there is increasing interest in other somatic gene mutations including epigenetic regulators, spliceosome components, transcription factors and oncogenes<sup><xref ref-type="bibr" rid="R12">12</xref></sup>. These parameters are key informants of risk stratification for patients with MF (MIPSS70<sup><xref ref-type="bibr" rid="R13">13</xref></sup>), yet clinical utility lags behind for the more indolent subtypes (PV &amp; ET) where additional genomic information currently has limited impact on patient management<sup><xref ref-type="bibr" rid="R14">14</xref></sup>. Thus, greater understanding of fundamental MPN pathobiology, in particular, the molecular and cellular basis of disease, is urgently required to discover novel mediators that can be leveraged for prognostic and therapeutic purposes in these chronic MPN subtypes.</p><p id="P6">Platelets have a well-established and integral role in maintaining vascular integrity and mediating hemostasis. Additionally, platelets and their cargo have been shown in numerous translational studies to influence a myriad of pathological processes including inflammation, immune responses, and malignancy<sup><xref ref-type="bibr" rid="R15">15</xref>–<xref ref-type="bibr" rid="R17">17</xref></sup>. Platelet hyperactivity and the procoagulant role of platelets is a hallmark of MPNs<sup><xref ref-type="bibr" rid="R18">18</xref><xref ref-type="bibr" rid="R19">19</xref>,<xref ref-type="bibr" rid="R20">20</xref></sup>. Yet, a comprehensive picture of the MPN platelet molecular profile is still lacking. In recent published work that serves as a prelude to this data<sup><xref ref-type="bibr" rid="R21">21</xref></sup>, we evaluated a large (n=120) cohort of MPN patients of all three chronic subtypes, and discovered progressive changes in platelet transcriptomic expression thus offering novel candidate signatures and deeper insights into MPN pathobiology (<italic>e.g.</italic> interferon response, immuno-thrombosis, and impaired proteostasis). However, to date, no studies have evaluated the unbiased platelet proteome in a sizeable clinical cohort of patients with MPN and the overlap of MPN platelet proteo-transcriptome therefore, not understood.</p><p id="P7">In the present study, with the objective of delineating the MPN proteo-transcriptomic landscape, we performed a comprehensive and untargeted quantitative profiling of the platelet proteome in a large (n= 140) cohort of patients with an established diagnosis of PV and ET. We demonstrate marked differences in platelet protein expression and discover novel MPN-altered pathways in platelets. Importantly, we validate, across two independent sites, candidate signatures from the MPN platelet transcriptome at the protein level. Together, this amounts to a comprehensive molecular profile of differential MPN pathobiology at high-sensitivity cellular resolution.</p></sec><sec id="S2" sec-type="results"><title>Results</title><sec id="S3"><title>Platelet proteo-transcriptome across multi-site MPN clinical cohorts</title><p id="P8">Patient samples were recruited for untargeted, quantitative proteomic analysis. Using established and standardized platelet isolation protocols (see Methods), we prepared purified platelets from peripheral blood samples of patients with an established diagnosis of MPN and a cohort of healthy controls recruited across two sites: Hospital Papa Giovanni XXIII, Bergamo, Italy and Mater Misericordiae University Hospital, Dublin, Ireland. Together, this platelet proteome compendium comprised of 140 human peripheral blood samples from healthy donors (n= 40) and World Health Organization–defined MPN patients (n= 59 ET, n= 41 PV). Pertinent clinical features are listed in <xref ref-type="table" rid="T1">Table 1A</xref> and shown in <xref ref-type="fig" rid="F1">Figure 1</xref>; including MPN subtype (<bold>A</bold>), somatic driver mutation status (<bold>B</bold>), sex (<bold>C</bold>), treatment (<bold>D</bold>), age (<bold>E</bold>), and platelet count (<bold>F</bold>). Any inter-patient variability in patient age, sex, and treatment as well as experimental batch effects were adjusted as confounding factors in all downstream expression analyses (see Methods).</p><p id="P9">For comparative proteo-transcriptomic analysis, we leveraged our published dataset of the MPN platelet transcriptome comprising of 120 human peripheral blood samples from healthy donors (n= 21) and World Health Organization-defined MPN patients (n= 99) (single center, Stanford University, CA). Clinical variables of patients from this independent cohort (PV n= 33; ET n= 24, control n= 21) are outlined in <xref ref-type="table" rid="T1">Table 1B</xref> and described extensively in the original publication<sup><xref ref-type="bibr" rid="R21">21</xref></sup>.</p></sec><sec id="S4"><title>MPN platelet proteome distinguishes disease phenotype and reveals prothrombotic, proinflammatory, and profibrotic signatures</title><p id="P10">Focusing for this study on the more prothrombotic subtypes of MPNs (PV and ET), we hypothesized that the platelet proteome differs in MPN subtypes and would offer insights into the underlying pathophysiology and the associated thrombotic phenotype. We compared platelet proteomic expression in PV and ET with that of healthy donors and discovered distinct signatures. Unsupervised principal component analysis (PCA) of MPN patients and controls (<xref ref-type="fig" rid="F2">Figure 2A</xref>) confirmed that the collective variability from the first two principal components was MPN disease status (26% of total variance, after adjusting for age, sex, treatment, and experimental batch).</p><p id="P11">A total of 1,952 platelet proteins were quantified across MPN and control samples. Differential expression (DE) analysis of proteomic data (volcano plot, <xref ref-type="fig" rid="F2">Figure 2B, C</xref>) efficiently distinguished each of the MPN subtypes and resulted in highly significant expression signatures (false discovery rate FDR &lt;0.05) with 227 proteins differentially regulated in ET (113 increased and 114 decreased), and 166 in PV (122 increased and 44 decreased) compared to healthy donors.</p><p id="P12">Differential markers in ET and PV highlight candidate proteins as potential mediators of the clinically encountered pro-thrombotic phenotype, including proteins associated with hypercoagulation (e.g. MMP1, SERPINH1, FcγRIIA, PDIA6) and drivers of inflammation (LGALS1, S100A6, SLC25A24, CD63). Select candidates are highlighted in <xref ref-type="fig" rid="F2">Figure 2B, C</xref> and discussed in detail in <xref ref-type="table" rid="T2">Table 2</xref>. Also, while the profibrotic phenotype of myelofibrosis is well-understood<sup><xref ref-type="bibr" rid="R22">22</xref></sup>, candidate markers (LGALS1, S100A6) in the early, more indolent subtypes of these chronic myeloid malignancies point to potential platelet mediators of fibrosis of relevance to MF.</p></sec><sec id="S5"><title>Differential platelet proteome in MPNs identifies potential mediators of disease phenotype</title><p id="P13">To better decipher the functional and biological significance of the observed proteomic changes, we performed pathway-enrichment analysis and identified signaling pathways that are differentially activated between MPN subtypes and controls (<xref ref-type="fig" rid="F3">Figure 3</xref>). Gene set enrichment analysis (GSEA, see Methods) found that MPN (stratified by subtypes; ET and PV) primarily induces pathways associated with the unfolded protein response. Impaired proteostasis is attributed<sup><xref ref-type="bibr" rid="R23">23</xref>,<xref ref-type="bibr" rid="R24">24</xref></sup> to endoplasmic reticulum stress (note overexpression of candidate proteins HYOU, PDIA6, HSP90B1 in this data, <xref ref-type="fig" rid="F2">Figure 2B</xref>). Moreover, among the most enriched gene sets, MPN pathology induces activation of oxidative phosphorylation (OXPHOS) and mTORC1 signaling pathways. Proliferation pathways also reveal significant enrichment with overexpression of c-MYC target proteins among patients with PV. Representative GSEA profiles are shown in <xref ref-type="fig" rid="F3">Figure 3</xref> and the full list of gene sets are detailed in <xref ref-type="supplementary-material" rid="SD1">Table S2A-B</xref>. The MPN pathways exhibiting significant proteomic regulation by GSEA are consistent with our observations at the individual level for increased or decreased protein expression and mirror key signaling pathways identified in our prior platelet transcriptomic analysis<sup><xref ref-type="bibr" rid="R21">21</xref></sup>. These results are also consistent with independent studies in MPN granulocytes<sup><xref ref-type="bibr" rid="R25">25</xref>,<xref ref-type="bibr" rid="R26">26</xref></sup> and hematopoietic stem and progenitor cells<sup><xref ref-type="bibr" rid="R27">27</xref>–<xref ref-type="bibr" rid="R29">29</xref></sup> confirming their significance in MPN pathobiology and as potential therapeutic modalities<sup><xref ref-type="bibr" rid="R30">30</xref></sup>.</p></sec><sec id="S6"><title>Shared platelet proteo-transcriptome by MPN subtype</title><p id="P14">Having defined differential protein signatures by MPN subtype, we proceeded to identify significant (FDR &lt; 0.05) shared signatures between the current platelet proteomic data and our prior transcriptomic data<sup><xref ref-type="bibr" rid="R21">21</xref></sup>. We found 214 differentially expressed markers (significant ones alone across MPNs) at both transcript and protein levels – together translating to a moderate correlation (Spearman’s rho =0.44) between each other (<xref ref-type="fig" rid="F4">Figure 4</xref>). In general, this is consistent with previous transcriptome-proteome comparative studies, including across species and matched cell-line experiments<sup><xref ref-type="bibr" rid="R31">31</xref>–<xref ref-type="bibr" rid="R33">33</xref></sup>.</p><p id="P15">Taking the overlap of the significantly differentially expressed proteins and genes (FDR &lt; 0.05) that were common across MPN subtypes (i.e., present in both ET and PV specimens), we identified highly expressed features (n= 17) shared between the two independent MPN ‘omic’ cohorts. Unsupervised hierarchical clustering further classified this core MPN platelet proteo-transcriptomic overlap for ET and PV subtypes, in contrast with that of healthy donors. <xref ref-type="fig" rid="F5">Figure 5</xref> demonstrates graded expression of 17 shared signatures between the MPN platelet proteome and transcriptome. Although MPN patients cluster into a group distinct from controls, we also note the overlay between PV and ET platelet signatures likely reflecting shared pathobiology. Most importantly, these signatures point to key molecular pathways previously identified in our MPN platelet transcriptome data and now validated at the protein level in the ET/PV platelet proteome (<xref ref-type="fig" rid="F2">Figures 2</xref>, <xref ref-type="fig" rid="F3">3</xref>, and <xref ref-type="fig" rid="F5">5</xref>). These include, for instance impaired proteostasis and ER stress (known markers<sup><xref ref-type="bibr" rid="R34">34</xref>–<xref ref-type="bibr" rid="R36">36</xref></sup> PSMD13, UNC45A, ATP6V1B2, NUCB1), oxidative stress and apoptosis<sup><xref ref-type="bibr" rid="R37">37</xref>–<xref ref-type="bibr" rid="R40">40</xref></sup> (MAOB, PSAP, VDAC1, TIMP1) and lipid metabolism<sup><xref ref-type="bibr" rid="R41">41</xref>–<xref ref-type="bibr" rid="R43">43</xref></sup> (ME1, DHCR7, FAH). Moreover, as shown earlier in <xref ref-type="fig" rid="F2">Figure 2B</xref>, known markers of platelet activation, classical coagulation factors and mediators of immunothrombosis such as FcγRIIA, F5, VWF LGALS1, and LGALS3BP, are also confirmed.</p><p id="P16">Thus together, this comprehensive proteo-transcriptomic analysis validating MPN platelet signatures not only between RNA and protein expression but also across two independent sites and clinical cohorts highlights additional underlying mechanisms beyond the MPN genetic landscape (and the known pivotal driver and nondriver mutations). The observed platelet molecular profile supports our hypothesis that platelets contribute to remodeling of the circulatory microenvironment which could lead to a self-reinforcing inflammatory milieu, possibly promoting disease progression and associated MPN vascular complications.</p></sec></sec><sec id="S7" sec-type="discussion"><title>Discussion</title><p id="P17">Here, we present a comprehensive proteo-transcriptomic study of blood platelet expression in patients with chronic progressive MPNs across international multi-site clinical cohorts (first of this kind to the best of our knowledge). Thrombocytosis is a cardinal feature of MPN, however platelet count in isolation is not predictive of clinical outcome<sup><xref ref-type="bibr" rid="R44">44</xref></sup>. Moreover, conventional anti-platelet therapy does not fully mitigate thrombotic risk and cytoreductive therapy has shown limited potential to alter natural history of the disease to date<sup><xref ref-type="bibr" rid="R45">45</xref></sup>. Recent data suggest<sup><xref ref-type="bibr" rid="R46">46</xref></sup> that disease course may be modified with targeted treatments, however options remain limited, with incomplete understanding of why patients fail first line therapy with few available alternatives. One approach that is increasingly recognized as highly valuable in identifying novel therapeutic targets as well as molecular markers of disease (especially at a systems level) is to leverage pertinent multi-omic<sup><xref ref-type="bibr" rid="R47">47</xref>–<xref ref-type="bibr" rid="R49">49</xref></sup> datasets.</p><p id="P18">In this study, we unravel the molecular phenotype of platelets, with a focus on the platelet proteome in the highly prothrombotic subtypes of MPN (PV and ET). Crucially, we validate this proteomic data with our prior MPN platelet transcriptomic data (ET, PV, and MF), confirming a strong possible role for platelet mechanisms in MPN pathobiology. Our data also expands on findings from other smaller or targeted studies, thus identifying the platelet proteo-transcriptome as potential mediators (and therefore, an invaluable biosource) of MPN proinflammatory, prothrombotic, and profibrotic processes<sup><xref ref-type="bibr" rid="R50">50</xref>–<xref ref-type="bibr" rid="R56">56</xref></sup>.</p><p id="P19">Our international collaborative effort demonstrates an example of addressing pertinent, global research questions (particularly for rare disorders such as MPNs). Importantly, this cross-institutional body of work emphasizes the value of standardized protocols in achieving larger cohort sizes and ensuring external validation toward high-quality and reproducible data of direct relevance to patient care<sup><xref ref-type="bibr" rid="R57">57</xref>,<xref ref-type="bibr" rid="R58">58</xref></sup>.</p><p id="P20">In conclusion, using label-free, untargeted platelet proteomic profiling, we discover key pathobiological mediators of thrombosis and proteostasis in MPN patients (focusing on ET and PV subtypes) from multiple recruitment sites; and validate the proteome with our prior transcriptomic data from an independent cohort.</p><p id="P21">We identify significant differential protein expression, that were also noted at the RNA level, thus strengthening biological insights, and revealing high priority candidate markers for functional evaluation in MPN studies. Our findings highlight the platelet molecular profile as a unique peripherally accessible window into MPN pathobiology. We also demonstrate the immense value of collaboration between groups with shared research goals and complementary expertise in increasing the feasibility of large-scale translational studies, particularly for rare disease cohorts.</p><sec id="S8"><title>Limitations of the study</title><p id="P22">There are several potential limitations of this study. Firstly, the comparative multi-omic measurements were not in the same patients, but in separate MPN clinical cohorts at independent sites. Consequently, there were limitations on the extent of integrative multi-omic analyses possible. However, our results do align with a recent independent but smaller study with paired MPN platelet multi-omic analysis<sup><xref ref-type="bibr" rid="R50">50</xref></sup>. Of note, there is increasing acknowledgement that a ‘rectangular approach’ using untargeted, discovery methodologies from large, geographically independent cohorts of patients at both the discovery and validation phases of biomarker research is superior to traditional ‘triangular workflow’, where hypothesis-free technologies are used initially followed by targeted validation of a smaller candidate markers in a larger sample size<sup><xref ref-type="bibr" rid="R59">59</xref></sup>. Secondly, in line with our hypothesis focusing on platelets as prothrombotic mediators we have limited our investigation to PV and ET patient samples. However, our analysis revealed the heterogeneity of the platelet proteome and implicated platelets in a diverse range of biological pathways (and confirming signatures identified in our prior MPN platelet transcriptomic data). We recognize that a longitudinal study following patients for the development of thrombotic outcomes (at adequate power) would be critical and will enable the development of future risk prediction algorithms. Thirdly, data-dependent acquisition mass spectrometry was carried out in this study, wherein a subset of the most abundant ions reaching the mass spectrometer detector are individually fragmented. Incomplete protein coverage is a well described limitation of this technique, particularly for low abundant proteins, and we recognize that failure to detect RNA-protein correlates in our platelet samples does not suggest absence at the protein level. Finally, we recognize that future mechanistic studies are needed to substantiate results from this study focused on characterizing the MPN platelet proteo- transcriptome alone. Our ongoing efforts include proteomic analysis of platelets from prospectively recruited patients at the time of initial MPN diagnosis to identify candidates for mechanistic interrogation in treatment naive patients and to better understand the platelet molecular signature as a potential diagnostic, prognostic, or therapeutic target for patients with MPN.</p></sec></sec><sec id="S9" sec-type="methods"><title>Methods</title><sec id="S10"><title>Study recruitment and sample preparation for platelet proteomics</title><p id="P23">Ethical approval was granted from the Institutional Review Board (IRB) of the Mater Misericordiae University Hospital, Dublin, Ireland (IRB approval number 1/378/2241) and the Papa Giovanni XXIII Hospital, Bergamo, Italy (IRB approval number 1789/2013). Patients over the age of 18 with an established diagnosis of MPN (PV n= 41, ET n= 59) according to the World Health Organization diagnostic classification and a control group of healthy donors (n= 40) were invited to participate (2014-2022)<sup><xref ref-type="bibr" rid="R60">60</xref></sup>. Following informed consent, samples of whole blood collected in sodium citrate (0.105mol/L) were obtained by direct venipuncture. Platelets were isolated from platelet rich plasma (PRP) obtained by centrifugation of whole blood for 10 minutes at 400 <italic>g</italic> at room temperature (RT), according to a published method<sup><xref ref-type="bibr" rid="R61">61</xref></sup>. Briefly, PRP was diluted in 1:2 ratio with Krebs Ringer buffer (4mM KCl, 107 mM NaCl, 20 mM NaHCo<sub>3</sub>, 2mM Na<sub>2</sub>SO<sub>4</sub>, pH 5). After centrifugation at 1,000 <italic>g</italic> for 10 min at RT, the platelet pellet was resuspended in Krebs Ringer buffer supplemented with glucose (0.9 g/L, PH 6) and centrifuged a second time (1,000 <italic>g</italic>, 10 min, RT). This washing procedure was repeated twice, and the platelets were resuspended at a concentration of 1x 10<sup>9</sup> platelets/mL in phosphate buffered saline (PBS) or PBS containing 1% Triton, snap frozen on dry ice and stored at -80 °C.</p></sec><sec id="S11"><title>Mass Spectrometry</title><p id="P24">Whole platelets were lysed in RIPA buffer (100 mM Tris pH 8.0, 300 mM NaCl, 2% Triton-X 100, 0.2% SDS, 1% sodium deoxycholate) with protease and phosphatase inhibitors (Roche). Samples were precipitated with 95% acetone overnight at -20 °C, centrifuged at 14,000 <italic>g</italic> at 4 °C for 10 minutes and the supernatant was removed. The protein pellet was resuspended in PBS and protein concentration was estimated by measuring absorbance at 280nm using a DS-11 spectrophotometer (DeNovix) as before<sup><xref ref-type="bibr" rid="R62">62</xref>,<xref ref-type="bibr" rid="R63">63</xref></sup>. Mass spectrometry sample preparation was performed using the commercially available PreOmics iST HT 192x kit (P.O.00067). In brief, 50 μg of protein was simultaneously lysed, reduced, and alkylated for 10 min at 95 °C and 1000 rpm, transferred to a cartridge and subsequently double-digested with LysC and trypsin at 37 °C and 500 rpm for 1 hour. Peptides were purified with repeated washes and eluted. Samples were evaporated at 45 °C and peptides resuspended in LC-load buffer. Digested peptides were loaded onto C18 trap columns (Evotip) and washed with 20 μL 0.1% formic acid (FA) followed by the addition of 100 μL storage solvent (0.1% FA). Differential proteomic signatures were established using label free liquid chromatography mass spectrometry (LC-MS) analyzed in a Bruker TimsTOF mass spectrometer connected to an EvoSep liquid chromatography system operated by the UCD Conway Proteomics Core facility.</p><p id="P25">Samples were loaded onto the Evosep One LC system and separated with an increasing acetonitrile gradient over 40 minutes at a flow rate of 250 nl/min at room temperature. The mass spectrometer was operated in positive ion mode with a capillary voltage of 1500V, dry gas flow of 3 l/min and a dry temperature of 180 °C. All data was acquired with the instrument operating in trapped ion mobility spectrometry (TIMS) mode. Trapped ions were selected for MS/MS using parallel accumulation serial fragmentation (PASEF).</p><p id="P26">Identified peptides from platelet samples were searched against a human FASTA (July, 2022) using MaxQuant (2.0.3.0) with specific parameters for trapped ion mobility spectra data dependent acquisition (TIMS DDA). In the main Andromeda search precursor, mass and fragment mass had an initial mass tolerance of 6 ppm and 20 ppm, respectively. The search included fixed modification of carbamidomethyl cysteine. Minimal peptide length was set to seven amino acids, and a maximum of two miscleavages was allowed. The false discovery rate (FDR) was set to 0.01 for peptide and protein identifications. The normalized protein intensity of each identified protein was used for label free quantitation (LFQ) as previously described<sup><xref ref-type="bibr" rid="R64">64</xref></sup>.</p></sec><sec id="S12"><title>Proteomic analyses</title><p id="P27">Statistical analysis of the LFQ intensities was performed using Perseus (version2.0.10) and R (version 4.3.1). Protein identifications were filtered to eliminate identifications from the reverse database, proteins only identified by site, and common contaminants. For downstream analysis, only proteins identified in at least 50% of samples in at least one group (control/ET/PV) were included. Missing values were imputed using the random forest method (Missforest package, R/Bioconductor). Data was log2-transformed and differential protein expression was established using the Limma software package within R/Bioconductor.</p><p id="P28">Differential protein expression was adjusted for batch, patient age, sex, and treatment (antiplatelet and cytoreductive therapy) as potential confounding variables within the linear model in Limma (design &lt;- model.matrix(~patientvar$Subtype+patientvar$Batch+patientvar$Age+patientvar$Sex+patientvar$ASAnum +patientvar$HYDnum). Controlling for multiple comparisons was performed using the Benjamini-Hochberg defined false discovery rate (FDR). Significant differential protein expression was pre-specified as proteins with an FDR &lt; 0.05 and a fold change of 1.5 in MPN, as compared to healthy controls.</p><p id="P29">Continuous data were summarized as medians and IQRs and categorical data are presented as frequencies and percentages. To compare differences in clinical variables between healthy controls and MPN subtypes (ET and PV), we used violin and box plots and conducted Mann-Whitney <italic>U</italic> test for non-parametric data. For unsupervised clustering and visualization, we performed principal component analyses (identifying MPN subtypes by color). All analyses were performed using the R studio interface (version 2023.03.1+446).</p></sec><sec id="S13"><title>Proteomic quality control and validation analysis</title><p id="P30">To assess intra-donor platelet proteomic reproducibility, 6 patient samples were analyzed as technical replicates (5 in duplicate, 1 in triplicate). Pearson correlation coefficient (<italic>r)</italic> was performed on the log2 transformed LFQ- intensity of all proteins quantified (n= 1771) across technical replicate samples. To assess biological (inter-donor) variability in protein abundances, Pearson correlation coefficient (<italic>r</italic>) was performed on the log2 transformed LFQ-intensity of all proteins quantified (n= 1952) across biologic replicate samples (control n= 40; MPN n= 100).</p></sec><sec id="S14"><title>Pathway/Gene set enrichment analysis for differentially expressed (DE) proteins</title><p id="P31">Gene set enrichment analysis(GSEA)<sup><xref ref-type="bibr" rid="R65">65</xref></sup>, a well-established method for determining regulatory patterns in coexpressed genes, was performed on the entire DE protein set for each MPN subtype (PV &amp; ET), using the Cancer Hallmarks gene sets from MSigDB<sup><xref ref-type="bibr" rid="R66">66</xref></sup>. The ‘GSEA Pre-ranked’ function was used with a metric score that combines fold change and adjusted p-value together for improved gene ranking. We used default settings with 10,000 gene set permutations to generate <italic>p</italic> and <italic>q</italic> values and compared MPN subtypes. In these analyses, to allow for a broad comparison, we assessed all transcripts that were differentially expressed according to FDR/adjusted p &lt; 0.25 as recommended by the authors of GSEA <sup><xref ref-type="bibr" rid="R65">65</xref></sup>.</p></sec><sec id="S15"><title>Transcriptomic analyses</title><p id="P32">For platelet transcriptomics, detailed methodology including platelet isolation, next generation RNA sequencing and platelet transcriptome analysis is outlined in the original publication<sup><xref ref-type="bibr" rid="R21">21</xref></sup>. Briefly, peripheral blood samples from 99 patients with MPN (ET n= 24, PV n= 33, MF n= 42) were obtained from the Stanford Cancer Institute Hematology Tissue Bank from December 2016- December 2019 and 21 healthy donors from the Stanford Blood Center. All blood samples were obtained with written informed patient or donor consent. Ethical approval was granted by the Stanford University Institutional Review Board (IRB approval #18329). RNA Sequencing was performed at the Stanford Genomics core. Platelet transcriptomic data were library-size-corrected, variance-stabilized, and log2-transformed using the R package DESeq2<sup><xref ref-type="bibr" rid="R67">67</xref></sup>.</p></sec><sec id="S16"><title>Comparative proteo-transcriptome analysis</title><p id="P33">Our published MPN platelet RNA sequencing dataset was used for comparative analysis with the MPN mass spectrometry proteomic data. Comparative analysis of these two independent ‘omic’ cohorts was established using direct feature overlap of significantly expressed genes and proteins (FDR &lt;0.05). Shared candidate markers between the two independent MPN -omic cohorts were evaluated for further analyses. We generated heatmaps of these common highly significant genes and proteins using the pheatmap R package and its built- in functions for hierarchical cluster analysis on the sample-to-sample Euclidean distance matrix of the expression data for each independent dataset. Spearman’s rank correlation coefficient (rho) was used to correlate differential gene expression (log2fold change) of common significant (FDR &lt; 0.05) genes and proteins between the independent MPN platelet proteomic and transcriptomic cohorts.</p></sec></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplementary Tables</label><media xlink:href="EMS190173-supplement-Supplementary_Tables.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d31aAdEbB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD2"><label>Supplementary Figure</label><media xlink:href="EMS190173-supplement-Supplementary_Figure.pdf" mimetype="application" mime-subtype="pdf" id="d31aAdEcB" position="anchor"/></supplementary-material></sec></body><back><ack id="S17"><title>Acknowledgments</title><p>This multi-institutional collaboration spearheaded by early-career investigators (S.K., B.K., and A.K.) would not be possible without the significant foundational efforts from senior investigators at each of our institutions. Specifically, we would like to thank Prof. Anna Falanga and her team at University of Milano-Bicocca and Papa Giovanni XXIII in Bergamo, Italy, Profs. Fionnuala Ni Ainle and Patricia Maguire at UCD Conway SPHERE Research Group, University College Dublin, Dublin, Ireland, and Profs. Holden Maecker and Jason Gotlib, and Ms. Cecelia Perkins at the Stanford MPN Translational Research Center and Stanford University.</p><p>S.K. received a Training Fellowship from the International Society of Thrombosis Haemostasis and the International Network of VENous Thromboembolism Clinical Research Networks (ISTH/INVENT) to complete this multi-site study with A.K. as host mentor at Stanford University. S.K. is additionally supported by a Wellcome Trust &amp; Health Research Board Irish Clinical and Academic Training (ICAT) fellowship. This work was also funded by US National Institutes of Health grants 1K08HG010061-01A1 (NHGRI), 3UL1TR001085-04S1 (NCATS), and the MPN Research Foundation to A.K, and additional partial support from U01HG011762 (GREGoR, PI Professor Stephen B Montgomery at Stanford).</p></ack><sec id="S18" sec-type="data-availability"><title>Data Sharing Statement</title><p id="P34">The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE<sup><xref ref-type="bibr" rid="R68">68</xref></sup> partner repository with the dataset identifier PXD046324. RNA-sequencing data from this work (original FASQ files from paired-end sequencing of all 120 samples) is already deposited to the NIH genomic data repository dbGAP under public accession # PHS-0021-21. v1.P1.</p></sec><fn-group><fn id="FN3" fn-type="con"><p id="P35"><bold>Authorship Contributions</bold> S. Kelliher, B. Kevane, and A. Krishnan conceived of the overall study and secured funding. S.K. designed the experimental plan with input from P.M., F.N.A., B.K. and A.K. S.K. and S.G. coordinated and performed the sample acquisition and processing according to established protocols. Z.S. and A.K. developed the code for computational analyses and A.K. and S.K. performed and interpreted the analyses. S. Madden and K.B. provided bioinformatic support. L.W. supported platelet protein preparation and C.S. operated mass spectrometry at the UCD Conway Proteomics Core Facility. Clinical samples, and annotation were kindly provided by A. Falanga and M.M., F.S. and S.G. at the Hospital Papa Giovanni XXIII, Bergamo, Italy. A. Fortune., S. Maung, M.F. provided clinical samples and annotation at the Mater Misericordiae University Hospital, Dublin, Ireland. S.K., and A.K. wrote and edited the manuscript. All authors critically reviewed and edited the manuscript. All authors approved the final manuscript.</p></fn></fn-group><ref-list><title>Bibliography</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khoury</surname><given-names>JD</given-names></name><name><surname>Solary</surname><given-names>E</given-names></name><name><surname>Abla</surname><given-names>O</given-names></name><etal/></person-group><article-title>The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms</article-title><source>Leukemia</source><year>2022</year><month>Jul</month><volume>36</volume><issue>7</issue><fpage>1703</fpage><lpage>1719</lpage><pub-id pub-id-type="pmcid">PMC9252913</pub-id><pub-id pub-id-type="pmid">35732831</pub-id><pub-id pub-id-type="doi">10.1038/s41375-022-01613-1</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gianelli</surname><given-names>U</given-names></name><name><surname>Thiele</surname><given-names>J</given-names></name><name><surname>Orazi</surname><given-names>A</given-names></name><etal/></person-group><article-title>International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms</article-title><source>Virchows Arch</source><year>2023</year><month>Jan</month><volume>482</volume><issue>1</issue><fpage>53</fpage><lpage>68</lpage><pub-id pub-id-type="pmcid">PMC9852206</pub-id><pub-id pub-id-type="pmid">36580136</pub-id><pub-id pub-id-type="doi">10.1007/s00428-022-03480-8</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hultcrantz</surname><given-names>M</given-names></name><name><surname>Bjorkholm</surname><given-names>M</given-names></name><name><surname>Dickman</surname><given-names>PW</given-names></name><etal/></person-group><article-title>Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms: A Population-Based Cohort Study</article-title><source>Ann Intern Med</source><year>2018</year><month>Mar</month><day>6</day><volume>168</volume><issue>5</issue><fpage>317</fpage><lpage>325</lpage><pub-id pub-id-type="pmcid">PMC7533681</pub-id><pub-id pub-id-type="pmid">29335713</pub-id><pub-id pub-id-type="doi">10.7326/M17-0028</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baumeister</surname><given-names>J</given-names></name><name><surname>Chatain</surname><given-names>N</given-names></name><name><surname>Sofias</surname><given-names>AM</given-names></name><name><surname>Lammers</surname><given-names>T</given-names></name><name><surname>Koschmieder</surname><given-names>S</given-names></name></person-group><article-title>Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives</article-title><source>Cells</source><year>2021</year><month>Dec</month><day>16</day><volume>10</volume><issue>12</issue><pub-id pub-id-type="pmcid">PMC8700229</pub-id><pub-id pub-id-type="pmid">34944059</pub-id><pub-id pub-id-type="doi">10.3390/cells10123551</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>D</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Variables associated with patient-reported outcomes in patients with myeloproliferative neoplasms</article-title><source>Leuk Lymphoma</source><year>2021</year><month>Nov</month><volume>62</volume><issue>11</issue><fpage>2703</fpage><lpage>2715</lpage><pub-id pub-id-type="pmid">34098836</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamulyak</surname><given-names>EN</given-names></name><name><surname>Daams</surname><given-names>JG</given-names></name><name><surname>Leebeek</surname><given-names>FWG</given-names></name><etal/></person-group><article-title>A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms</article-title><source>Blood Adv</source><year>2021</year><month>Jan</month><day>12</day><volume>5</volume><issue>1</issue><fpage>113</fpage><lpage>121</lpage><pub-id pub-id-type="pmcid">PMC7805324</pub-id><pub-id pub-id-type="pmid">33570633</pub-id><pub-id pub-id-type="doi">10.1182/bloodadvances.2020003628</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbui</surname><given-names>T</given-names></name><name><surname>De Stefano</surname><given-names>V</given-names></name><name><surname>Falanga</surname><given-names>A</given-names></name><etal/></person-group><article-title>Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper</article-title><source>Blood Cancer J</source><year>2019</year><month>Aug</month><day>8</day><volume>9</volume><issue>8</issue><fpage>61</fpage><pub-id pub-id-type="pmcid">PMC6687826</pub-id><pub-id pub-id-type="pmid">31395856</pub-id><pub-id pub-id-type="doi">10.1038/s41408-019-0225-5</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falanga</surname><given-names>A</given-names></name><name><surname>Marchetti</surname><given-names>M</given-names></name></person-group><article-title>Cancer-associated thrombosis: enhanced awareness and pathophysiologic complexity</article-title><source>J Thromb Haemost</source><year>2023</year><month>Jun</month><volume>21</volume><issue>6</issue><fpage>1397</fpage><lpage>1408</lpage><pub-id pub-id-type="pmid">36931602</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falanga</surname><given-names>A</given-names></name><name><surname>Marchetti</surname><given-names>M</given-names></name></person-group><article-title>Thrombotic disease in the myeloproliferative neoplasms</article-title><source>Hematology Am Soc Hematol Educ Program</source><year>2012</year><volume>2012</volume><fpage>571</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">23233637</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tefferi</surname><given-names>A</given-names></name><name><surname>Barbui</surname><given-names>T</given-names></name></person-group><article-title>Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, riskstratification and management</article-title><source>Am J Hematol</source><year>2019</year><month>Jan</month><volume>94</volume><issue>1</issue><fpage>133</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">30281843</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vannucchi</surname><given-names>AM</given-names></name><name><surname>Guglielmelli</surname><given-names>P</given-names></name></person-group><article-title>Molecular prognostication in Ph-negative MPNs in 2022</article-title><source>Hematology Am Soc Hematol Educ Program</source><year>2022</year><month>Dec</month><day>9</day><volume>2022</volume><issue>1</issue><fpage>225</fpage><lpage>234</lpage><pub-id pub-id-type="pmcid">PMC9820187</pub-id><pub-id pub-id-type="pmid">36485130</pub-id><pub-id pub-id-type="doi">10.1182/hematology.2022000339</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marneth</surname><given-names>AE</given-names></name><name><surname>Mullally</surname><given-names>A</given-names></name></person-group><article-title>The Molecular Genetics of Myeloproliferative Neoplasms</article-title><source>Cold Spring Harb Perspect Med</source><year>2020</year><month>Feb</month><day>3</day><volume>10</volume><issue>2</issue><pub-id pub-id-type="pmcid">PMC6996444</pub-id><pub-id pub-id-type="pmid">31548225</pub-id><pub-id pub-id-type="doi">10.1101/cshperspect.a034876</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tefferi</surname><given-names>A</given-names></name><name><surname>Guglielmelli</surname><given-names>P</given-names></name><name><surname>Lasho</surname><given-names>TL</given-names></name><etal/></person-group><article-title>MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis</article-title><source>J Clin Oncol</source><year>2018</year><month>Jun</month><day>10</day><volume>36</volume><issue>17</issue><fpage>1769</fpage><lpage>1770</lpage><pub-id pub-id-type="pmid">29708808</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cross</surname><given-names>NCP</given-names></name><name><surname>Godfrey</surname><given-names>AL</given-names></name><name><surname>Cargo</surname><given-names>C</given-names></name><name><surname>Garg</surname><given-names>M</given-names></name><name><surname>Mead</surname><given-names>AJ</given-names></name></person-group><article-title>The use of genetic tests to diagnose and manage patients with myeloproliferative and myeloproliferative/myelodysplastic neoplasms, and related disorders</article-title><source>Br J Haematol</source><year>2021</year><month>Nov</month><volume>195</volume><issue>3</issue><fpage>338</fpage><lpage>351</lpage><pub-id pub-id-type="pmid">34409596</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aslan</surname><given-names>JE</given-names></name></person-group><article-title>Platelet Proteomes, Pathways, and Phenotypes as Informants of Vascular Wellness and Disease</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2021</year><month>Mar</month><volume>41</volume><issue>3</issue><fpage>999</fpage><lpage>1011</lpage><pub-id pub-id-type="pmcid">PMC7980774</pub-id><pub-id pub-id-type="pmid">33441027</pub-id><pub-id pub-id-type="doi">10.1161/ATVBAHA.120.314647</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franco</surname><given-names>AT</given-names></name><name><surname>Corken</surname><given-names>A</given-names></name><name><surname>Ware</surname><given-names>J</given-names></name></person-group><article-title>Platelets at the interface of thrombosis, inflammation, and cancer</article-title><source>Blood</source><year>2015</year><month>Jul</month><day>30</day><volume>126</volume><issue>5</issue><fpage>582</fpage><lpage>8</lpage><pub-id pub-id-type="pmcid">PMC4520875</pub-id><pub-id pub-id-type="pmid">26109205</pub-id><pub-id pub-id-type="doi">10.1182/blood-2014-08-531582</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denorme</surname><given-names>F</given-names></name><name><surname>Campbell</surname><given-names>RA</given-names></name></person-group><article-title>Procoagulant platelets: novel players in thromboinflammation</article-title><source>Am J Physiol Cell Physiol</source><year>2022</year><month>Oct</month><day>1</day><volume>323</volume><issue>4</issue><fpage>C951</fpage><lpage>c958</lpage><pub-id pub-id-type="pmcid">PMC9484986</pub-id><pub-id pub-id-type="pmid">35993516</pub-id><pub-id pub-id-type="doi">10.1152/ajpcell.00252.2022</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arellano-Rodrigo</surname><given-names>E</given-names></name><name><surname>Alvarez-Larran</surname><given-names>A</given-names></name><name><surname>Reverter</surname><given-names>JC</given-names></name><name><surname>Villamor</surname><given-names>N</given-names></name><name><surname>Colomer</surname><given-names>D</given-names></name><name><surname>Cervantes</surname><given-names>F</given-names></name></person-group><article-title>Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status</article-title><source>Haematologica</source><year>2006</year><month>Feb</month><volume>91</volume><issue>2</issue><fpage>169</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">16461300</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><collab>Thrombosis: a major contributor to the global disease burden</collab><article-title>Isth Steering Committee for World Thrombosis Day</article-title><source>J Thromb Haemost</source><year>2014</year><month>Oct</month><volume>12</volume><issue>10</issue><fpage>1580</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">25302663</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panova-Noeva</surname><given-names>M</given-names></name><name><surname>Marchetti</surname><given-names>M</given-names></name><name><surname>Buoro</surname><given-names>S</given-names></name><etal/></person-group><article-title>JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients</article-title><source>Blood</source><year>2011</year><month>Sep</month><day>1</day><volume>118</volume><issue>9</issue><fpage>2599</fpage><lpage>601</lpage><pub-id pub-id-type="pmid">21750318</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>Z</given-names></name><name><surname>Du</surname><given-names>W</given-names></name><name><surname>Perkins</surname><given-names>C</given-names></name><etal/></person-group><article-title>Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms</article-title><source>Cell Rep Med</source><year>2021</year><month>Oct</month><day>19</day><volume>2</volume><issue>10</issue><elocation-id>100425</elocation-id><pub-id pub-id-type="pmcid">PMC8561315</pub-id><pub-id pub-id-type="pmid">34755136</pub-id><pub-id pub-id-type="doi">10.1016/j.xcrm.2021.100425</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koschmieder</surname><given-names>S</given-names></name><name><surname>Chatain</surname><given-names>N</given-names></name></person-group><article-title>Role of inflammation in the biology of myeloproliferative neoplasms</article-title><source>Blood Rev</source><year>2020</year><month>Jul</month><volume>42</volume><elocation-id>100711</elocation-id><pub-id pub-id-type="pmid">32505517</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almanza</surname><given-names>A</given-names></name><name><surname>Carlesso</surname><given-names>A</given-names></name><name><surname>Chintha</surname><given-names>C</given-names></name><etal/></person-group><article-title>Endoplasmic reticulum stress signalling - from basic mechanisms to clinical applications</article-title><source>FEBS J</source><year>2019</year><volume>286</volume><issue>2</issue><fpage>241</fpage><lpage>278</lpage><comment>2019</comment><pub-id pub-id-type="pmcid">PMC7379631</pub-id><pub-id pub-id-type="pmid">30027602</pub-id><pub-id pub-id-type="doi">10.1111/febs.14608</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa-Mattioli</surname><given-names>M</given-names></name><name><surname>Walter</surname><given-names>P</given-names></name></person-group><article-title>The integrated stress response: From mechanism to disease</article-title><source>Science</source><year>2020</year><month>04</month><day>24</day><volume>368</volume><issue>6489</issue><comment>2020</comment><pub-id pub-id-type="pmcid">PMC8997189</pub-id><pub-id pub-id-type="pmid">32327570</pub-id><pub-id pub-id-type="doi">10.1126/science.aat5314</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cokic</surname><given-names>VP</given-names></name><name><surname>Mossuz</surname><given-names>P</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><etal/></person-group><article-title>Microarray and Proteomic Analyses of Myeloproliferative Neoplasms with a Highlight on the mTOR Signaling Pathway</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><issue>8</issue><elocation-id>e0135463</elocation-id><pub-id pub-id-type="pmcid">PMC4537205</pub-id><pub-id pub-id-type="pmid">26275051</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0135463</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tognon</surname><given-names>R</given-names></name><name><surname>Almeida</surname><given-names>ESDC</given-names></name><name><surname>Andraos-Rey</surname><given-names>R</given-names></name><etal/></person-group><article-title>A proteomic study of myeloproliferative neoplasms using reverse-phase protein arrays</article-title><source>Leuk Lymphoma</source><year>2020</year><month>Dec</month><volume>61</volume><issue>13</issue><fpage>3052</fpage><lpage>3065</lpage><pub-id pub-id-type="pmid">32799592</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartalucci</surname><given-names>N</given-names></name><name><surname>Tozzi</surname><given-names>L</given-names></name><name><surname>Bogani</surname><given-names>C</given-names></name><etal/></person-group><article-title>Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms</article-title><source>J Cell Mol Med</source><year>2013</year><month>Nov</month><volume>17</volume><issue>11</issue><fpage>1385</fpage><lpage>96</lpage><pub-id pub-id-type="pmcid">PMC4117551</pub-id><pub-id pub-id-type="pmid">24237791</pub-id><pub-id pub-id-type="doi">10.1111/jcmm.12162</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibarra</surname><given-names>J</given-names></name><name><surname>Elbanna</surname><given-names>YA</given-names></name><name><surname>Kurylowicz</surname><given-names>K</given-names></name><etal/></person-group><article-title>Type I but Not Type II Calreticulin Mutations Activate the IRE1a/XBP1 Pathway of the Unfolded Protein Response to Drive Myeloproliferative Neoplasms</article-title><source>Blood Cancer Discov</source><year>2022</year><month>Jul</month><day>6</day><volume>3</volume><issue>4</issue><fpage>298</fpage><lpage>315</lpage><pub-id pub-id-type="pmcid">PMC9338758</pub-id><pub-id pub-id-type="pmid">35405004</pub-id><pub-id pub-id-type="doi">10.1158/2643-3230.BCD-21-0144</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>G</given-names></name><name><surname>You</surname><given-names>X</given-names></name><name><surname>Wen</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Downregulating Notch counteracts Kras(G12D)-induced ERK activation and oxidative phosphorylation in myeloproliferative neoplasm</article-title><source>Leukemia</source><year>2019</year><month>Mar</month><volume>33</volume><issue>3</issue><fpage>671</fpage><lpage>685</lpage><pub-id pub-id-type="pmcid">PMC6405304</pub-id><pub-id pub-id-type="pmid">30206308</pub-id><pub-id pub-id-type="doi">10.1038/s41375-018-0248-0</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saenz</surname><given-names>DT</given-names></name><name><surname>Fiskus</surname><given-names>W</given-names></name><name><surname>Mill</surname><given-names>CP</given-names></name><etal/></person-group><article-title>Mechanistic basis and efficacy of targeting the p-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors</article-title><source>Blood</source><year>2020</year><month>Apr</month><day>9</day><volume>135</volume><issue>15</issue><fpage>1255</fpage><lpage>1269</lpage><pub-id pub-id-type="pmcid">PMC7146021</pub-id><pub-id pub-id-type="pmid">32068780</pub-id><pub-id pub-id-type="doi">10.1182/blood.2019002922</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haider</surname><given-names>S</given-names></name><name><surname>Pal</surname><given-names>R</given-names></name></person-group><article-title>Integrated analysis of transcriptomic and proteomic data</article-title><source>Curr Genomics</source><year>2013</year><month>Apr</month><volume>14</volume><issue>2</issue><fpage>91</fpage><lpage>110</lpage><pub-id pub-id-type="pmcid">PMC3637682</pub-id><pub-id pub-id-type="pmid">24082820</pub-id><pub-id pub-id-type="doi">10.2174/1389202911314020003</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buccitelli</surname><given-names>C</given-names></name><name><surname>Selbach</surname><given-names>M</given-names></name></person-group><article-title>mRNAs, proteins and the emerging principles of gene expression control</article-title><source>Nat Rev Genet</source><year>2020</year><month>Oct</month><volume>21</volume><issue>10</issue><fpage>630</fpage><lpage>644</lpage><pub-id pub-id-type="pmid">32709985</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karczewski</surname><given-names>KJ</given-names></name><name><surname>Snyder</surname><given-names>MP</given-names></name></person-group><article-title>Integrative omics for health and disease</article-title><source>Nat Rev Genet</source><year>2018</year><month>May</month><volume>19</volume><issue>5</issue><fpage>299</fpage><lpage>310</lpage><pub-id pub-id-type="pmcid">PMC5990367</pub-id><pub-id pub-id-type="pmid">29479082</pub-id><pub-id pub-id-type="doi">10.1038/nrg.2018.4</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>A</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Interlukin-4 weakens resistance to stress injury and megakaryocytic differentiation of hematopoietic stem cells by inhibiting Psmd13 expression</article-title><source>Sci Rep</source><year>2023</year><month>Aug</month><day>31</day><volume>13</volume><issue>1</issue><elocation-id>14253</elocation-id><pub-id pub-id-type="pmcid">PMC10471741</pub-id><pub-id pub-id-type="pmid">37653079</pub-id><pub-id pub-id-type="doi">10.1038/s41598-023-41479-6</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisa</surname><given-names>NH</given-names></name><name><surname>Jilani</surname><given-names>Y</given-names></name><name><surname>Kainth</surname><given-names>K</given-names></name><etal/></person-group><article-title>The co-chaperone UNC45A is essential for the expression of mitotic kinase NEK7 and tumorigenesis</article-title><source>J Biol Chem</source><year>2019</year><month>Apr</month><day>5</day><volume>294</volume><issue>14</issue><fpage>5246</fpage><lpage>5260</lpage><pub-id pub-id-type="pmcid">PMC6462532</pub-id><pub-id pub-id-type="pmid">30737284</pub-id><pub-id pub-id-type="doi">10.1074/jbc.RA118.006597</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hua</surname><given-names>YQ</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Sheng</surname><given-names>J</given-names></name><etal/></person-group><article-title>NUCB1 Suppresses Growth and Shows Additive Effects With Gemcitabine in Pancreatic Ductal Adenocarcinoma via the Unfolded Protein Response</article-title><source>Front Cell Dev Biol</source><year>2021</year><volume>9</volume><elocation-id>641836</elocation-id><pub-id pub-id-type="pmcid">PMC8041069</pub-id><pub-id pub-id-type="pmid">33855021</pub-id><pub-id pub-id-type="doi">10.3389/fcell.2021.641836</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maggiorani</surname><given-names>D</given-names></name><name><surname>Manzella</surname><given-names>N</given-names></name><name><surname>Edmondson</surname><given-names>DE</given-names></name><etal/></person-group><article-title>Monoamine Oxidases, Oxidative Stress, and Altered Mitochondrial Dynamics in Cardiac Ageing</article-title><source>Oxid Med Cell Longev</source><year>2017</year><volume>2017</volume><elocation-id>3017947</elocation-id><pub-id pub-id-type="pmcid">PMC5435992</pub-id><pub-id pub-id-type="pmid">28546851</pub-id><pub-id pub-id-type="doi">10.1155/2017/3017947</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>ZJ</given-names></name><name><surname>Fu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Proapoptotic Mitochondrial Carrier Homolog Protein PSAP Mediates Death Receptor 6 Induced Apoptosis</article-title><source>J Alzheimers Dis</source><year>2020</year><volume>74</volume><issue>4</issue><fpage>1097</fpage><lpage>1106</lpage><pub-id pub-id-type="pmid">32144986</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaouali</surname><given-names>MA</given-names></name><name><surname>Panisello</surname><given-names>A</given-names></name><name><surname>Lopez</surname><given-names>A</given-names></name><etal/></person-group><article-title>GSK3P and VDAC Involvement in ER Stress and Apoptosis Modulation during Orthotopic Liver Transplantation</article-title><source>Int J Mol Sci</source><year>2017</year><month>Mar</month><day>8</day><volume>18</volume><issue>3</issue><pub-id pub-id-type="pmcid">PMC5372607</pub-id><pub-id pub-id-type="pmid">28282906</pub-id><pub-id pub-id-type="doi">10.3390/ijms18030591</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Lin</surname><given-names>B</given-names></name><name><surname>Brems</surname><given-names>JJ</given-names></name><name><surname>Gamelli</surname><given-names>RL</given-names></name></person-group><article-title>Hepatic apoptosis can modulate liver fibrosis through TIMP1 pathway</article-title><source>Apoptosis</source><year>2013</year><month>May</month><volume>18</volume><issue>5</issue><fpage>566</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">23456624</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>Q</given-names></name><name><surname>Wei</surname><given-names>T</given-names></name><name><surname>Jia</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Dendrimer-Based Lipid Nanoparticles Deliver Therapeutic FAH mRNA to Normalize Liver Function and Extend Survival in a Mouse Model of Hepatorenal Tyrosinemia Type I</article-title><source>Adv Mater</source><year>2018</year><month>Dec</month><volume>30</volume><issue>52</issue><elocation-id>e1805308</elocation-id><pub-id pub-id-type="pmid">30368954</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Si</surname><given-names>Y</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Zhuo</surname><given-names>S</given-names></name><name><surname>Cui</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group><article-title>Prognostic value of lipid metabolism-related genes in head and neck squamous cell carcinoma</article-title><source>Immun Inflamm Dis</source><year>2021</year><month>Mar</month><volume>9</volume><issue>1</issue><fpage>196</fpage><lpage>209</lpage><pub-id pub-id-type="pmcid">PMC7860527</pub-id><pub-id pub-id-type="pmid">33277966</pub-id><pub-id pub-id-type="doi">10.1002/iid3.379</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Gu</surname><given-names>L</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><etal/></person-group><article-title>Dynamic Regulation of ME1 Phosphorylation and Acetylation Affects Lipid Metabolism and Colorectal Tumorigenesis</article-title><source>Mol Cell</source><year>2020</year><month>Jan</month><day>2</day><volume>77</volume><issue>1</issue><fpage>138</fpage><lpage>149</lpage><elocation-id>e5</elocation-id><pub-id pub-id-type="pmid">31735643</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moliterno</surname><given-names>AR</given-names></name><name><surname>Ginzburg</surname><given-names>YZ</given-names></name><name><surname>Hoffman</surname><given-names>R</given-names></name></person-group><article-title>Clinical insights into the origins of thrombosis in myeloproliferative neoplasms</article-title><source>Blood</source><year>2021</year><month>Mar</month><day>4</day><volume>137</volume><issue>9</issue><fpage>1145</fpage><lpage>1153</lpage><pub-id pub-id-type="pmcid">PMC8215376</pub-id><pub-id pub-id-type="pmid">33237986</pub-id><pub-id pub-id-type="doi">10.1182/blood.2020008043</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tefferi</surname><given-names>A</given-names></name></person-group><article-title>Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management</article-title><source>Am J Hematol</source><year>2023</year><month>May</month><volume>98</volume><issue>5</issue><fpage>801</fpage><lpage>821</lpage><pub-id pub-id-type="pmid">36680511</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>CN</given-names></name><name><surname>Nangalia</surname><given-names>J</given-names></name><name><surname>Boucher</surname><given-names>R</given-names></name><etal/></person-group><article-title>Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial</article-title><source>J Clin Oncol</source><year>2023</year><month>May</month><day>1</day><elocation-id>Jco2201935</elocation-id><pub-id pub-id-type="pmcid">PMC10306428</pub-id><pub-id pub-id-type="pmid">37126762</pub-id><pub-id pub-id-type="doi">10.1200/JCO.22.01935</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Heemskerk</surname><given-names>JWM</given-names></name><name><surname>Swieringa</surname><given-names>F</given-names></name></person-group><article-title>Combining human platelet proteomes and transcriptomes: possibilities and challenges</article-title><source>Platelets</source><year>2023</year><month>Dec</month><volume>34</volume><issue>1</issue><elocation-id>2224454</elocation-id><pub-id pub-id-type="pmid">37313659</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solari</surname><given-names>FA</given-names></name><name><surname>Krahn</surname><given-names>D</given-names></name><name><surname>Swieringa</surname><given-names>F</given-names></name><etal/></person-group><article-title>Multi-omics approaches to study platelet mechanisms</article-title><source>Curr Opin Chem Biol</source><year>2023</year><month>Apr</month><volume>73</volume><elocation-id>102253</elocation-id><pub-id pub-id-type="pmid">36689818</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Wispelaere</surname><given-names>K</given-names></name><name><surname>Freson</surname><given-names>K</given-names></name></person-group><article-title>The Analysis of the Human Megakaryocyte and Platelet Coding Transcriptome in Healthy and Diseased Subjects</article-title><source>Int J Mol Sci</source><year>2022</year><month>Jul</month><day>11</day><volume>23</volume><issue>14</issue><pub-id pub-id-type="pmcid">PMC9317744</pub-id><pub-id pub-id-type="pmid">35886993</pub-id><pub-id pub-id-type="doi">10.3390/ijms23147647</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>F</given-names></name><name><surname>Laranjeira</surname><given-names>ABA</given-names></name><name><surname>Kong</surname><given-names>T</given-names></name><etal/></person-group><article-title>Multiomic Profiling Reveals Metabolic Alterations Mediating Aberrant Platelet Activity and Inflammation in Myeloproliferative Neoplasms</article-title><source>bioRxiv</source><year>2022</year><elocation-id>2022.12.08.519689</elocation-id><pub-id pub-id-type="pmid">38060311</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharda</surname><given-names>AV</given-names></name><name><surname>Bogue</surname><given-names>T</given-names></name><name><surname>Barr</surname><given-names>A</given-names></name><name><surname>Mendez</surname><given-names>LM</given-names></name><name><surname>Flaumenhaft</surname><given-names>R</given-names></name><name><surname>Zwicker</surname><given-names>JI</given-names></name></person-group><article-title>Circulating Protein Disulfide Isomerase Is Associated with Increased Risk of Thrombosis in JAK2-Mutated Myeloproliferative Neoplasms</article-title><source>Clin Cancer Res</source><year>2021</year><month>Oct</month><day>15</day><volume>27</volume><issue>20</issue><fpage>5708</fpage><lpage>5717</lpage><pub-id pub-id-type="pmcid">PMC9170286</pub-id><pub-id pub-id-type="pmid">34400417</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-21-1140</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>SF</given-names></name><name><surname>Hunter</surname><given-names>RW</given-names></name><name><surname>Harper</surname><given-names>MT</given-names></name><etal/></person-group><article-title>Dysfunction of the PI3 kinase/Rap1/integrin a(IIb)P(3) pathway underlies ex vivo platelet hypoactivity in essential thrombocythemia</article-title><source>Blood</source><year>2013</year><month>Feb</month><day>14</day><volume>121</volume><issue>7</issue><fpage>1209</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">23243278</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pecci</surname><given-names>A</given-names></name><name><surname>Necchi</surname><given-names>V</given-names></name><name><surname>Barozzi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Particulate cytoplasmic structures with high concentration of ubiquitin-proteasome accumulate in myeloid neoplasms</article-title><source>J Hematol Oncol</source><year>2015</year><month>Jun</month><day>18</day><volume>8</volume><fpage>71</fpage><pub-id pub-id-type="pmcid">PMC4473848</pub-id><pub-id pub-id-type="pmid">26081257</pub-id><pub-id pub-id-type="doi">10.1186/s13045-015-0169-6</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pourcelot</surname><given-names>E</given-names></name><name><surname>Trocme</surname><given-names>C</given-names></name><name><surname>Mondet</surname><given-names>J</given-names></name><name><surname>Bailly</surname><given-names>S</given-names></name><name><surname>Toussaint</surname><given-names>B</given-names></name><name><surname>Mossuz</surname><given-names>P</given-names></name></person-group><article-title>Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications</article-title><source>Exp Hematol</source><year>2014</year><month>May</month><volume>42</volume><issue>5</issue><fpage>360</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">24463275</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Randi</surname><given-names>ML</given-names></name><name><surname>Brunati</surname><given-names>AM</given-names></name><name><surname>Scapin</surname><given-names>M</given-names></name><etal/></person-group><article-title>Src tyrosine kinase preactivation is associated with platelet hypersensitivity in essential thrombocythemia and polycythemia vera</article-title><source>Blood</source><year>2010</year><month>Jan</month><day>21</day><volume>115</volume><issue>3</issue><fpage>667</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">19965650</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fel</surname><given-names>A</given-names></name><name><surname>Lewandowska</surname><given-names>AE</given-names></name><name><surname>Petrides</surname><given-names>PE</given-names></name><name><surname>Wisniewski</surname><given-names>JR</given-names></name></person-group><article-title>Comparison of Proteome Composition of Serum Enriched in Extracellular Vesicles Isolated from Polycythemia Vera Patients and Healthy Controls</article-title><source>Proteomes</source><year>2019</year><month>May</month><day>6</day><volume>7</volume><issue>2</issue><pub-id pub-id-type="pmcid">PMC6631625</pub-id><pub-id pub-id-type="pmid">31064135</pub-id><pub-id pub-id-type="doi">10.3390/proteomes7020020</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krishnan</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>S</given-names></name></person-group><article-title>Toward platelet transcriptomics in cancer diagnosis, prognosis and therapy</article-title><source>Br J Cancer</source><year>2022</year><month>Feb</month><volume>126</volume><issue>3</issue><fpage>316</fpage><lpage>322</lpage><pub-id pub-id-type="pmcid">PMC8810955</pub-id><pub-id pub-id-type="pmid">34811507</pub-id><pub-id pub-id-type="doi">10.1038/s41416-021-01627-z</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>A</given-names></name></person-group><article-title>Platelet clinical proteomics: Facts, challenges, and future perspectives</article-title><source>Proteomics Clin Appl</source><year>2016</year><month>Aug</month><volume>10</volume><issue>8</issue><fpage>767</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">26948058</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geyer</surname><given-names>PE</given-names></name><name><surname>Holdt</surname><given-names>LM</given-names></name><name><surname>Teupser</surname><given-names>D</given-names></name><name><surname>Mann</surname><given-names>M</given-names></name></person-group><article-title>Revisiting biomarker discovery by plasma proteomics</article-title><source>Mol Syst Biol</source><year>2017</year><month>Sep</month><day>26</day><volume>13</volume><issue>9</issue><fpage>942</fpage><pub-id pub-id-type="pmcid">PMC5615924</pub-id><pub-id pub-id-type="pmid">28951502</pub-id><pub-id pub-id-type="doi">10.15252/msb.20156297</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arber</surname><given-names>DA</given-names></name><name><surname>Orazi</surname><given-names>A</given-names></name><name><surname>Hasserjian</surname><given-names>R</given-names></name><etal/></person-group><article-title>The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia</article-title><source>Blood</source><year>2016</year><month>May</month><day>19</day><volume>127</volume><issue>20</issue><fpage>2391</fpage><lpage>405</lpage><pub-id pub-id-type="pmid">27069254</pub-id></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortelazzo</surname><given-names>S</given-names></name><name><surname>Marchetti</surname><given-names>M</given-names></name><name><surname>Orlando</surname><given-names>E</given-names></name><name><surname>Falanga</surname><given-names>A</given-names></name><name><surname>Barbui</surname><given-names>T</given-names></name><name><surname>Buchanan</surname><given-names>MR</given-names></name></person-group><article-title>Aspirin increases the bleeding side effects in essential thrombocythemia independent of the cyclooxygenase pathway: role of the lipoxygenase pathway</article-title><source>Am J Hematol</source><year>1998</year><month>Apr</month><volume>57</volume><issue>4</issue><fpage>277</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">9544970</pub-id></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parsons</surname><given-names>MEM</given-names></name><name><surname>Szklanna</surname><given-names>PB</given-names></name><name><surname>Guerrero</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Platelet Releasate Proteome Profiling Reveals a Core Set of Proteins with Low Variance between Healthy Adults</article-title><source>Proteomics</source><year>2018</year><month>Aug</month><volume>18</volume><issue>15</issue><elocation-id>e1800219</elocation-id><pub-id pub-id-type="pmid">29932309</pub-id></element-citation></ref><ref id="R63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szklanna</surname><given-names>PB</given-names></name><name><surname>Parsons</surname><given-names>ME</given-names></name><name><surname>Wynne</surname><given-names>K</given-names></name><etal/></person-group><article-title>The Platelet Releasate is Altered in Human Pregnancy</article-title><source>Proteomics Clin Appl</source><year>2019</year><month>May</month><volume>13</volume><issue>3</issue><elocation-id>e1800162</elocation-id><pub-id pub-id-type="pmid">30318839</pub-id></element-citation></ref><ref id="R64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>L</given-names></name><name><surname>Keaney</surname><given-names>J</given-names></name><name><surname>Szklanna</surname><given-names>PB</given-names></name><etal/></person-group><article-title>Nonvalvular atrial fibrillation patients anticoagulated with rivaroxaban compared with warfarin exhibit reduced circulating extracellular vesicles with attenuated pro-inflammatory protein signatures</article-title><source>J Thromb Haemost</source><year>2021</year><month>Oct</month><volume>19</volume><issue>10</issue><fpage>2583</fpage><lpage>2595</lpage><pub-id pub-id-type="pmid">34161660</pub-id></element-citation></ref><ref id="R65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name><etal/></person-group><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>Proc Natl Acad Sci U S A</source><year>2005</year><month>Oct</month><day>25</day><volume>102</volume><issue>43</issue><fpage>15545</fpage><lpage>50</lpage><pub-id pub-id-type="pmcid">PMC1239896</pub-id><pub-id pub-id-type="pmid">16199517</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id></element-citation></ref><ref id="R66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liberzon</surname><given-names>A</given-names></name><name><surname>Birger</surname><given-names>C</given-names></name><name><surname>Thorvaldsdottir</surname><given-names>H</given-names></name><name><surname>Ghandi</surname><given-names>M</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name></person-group><article-title>The Molecular Signatures Database (MSigDB) hallmark gene set collection</article-title><source>Cell Syst</source><year>2015</year><month>Dec</month><day>23</day><volume>1</volume><issue>6</issue><fpage>417</fpage><lpage>425</lpage><pub-id pub-id-type="pmcid">PMC4707969</pub-id><pub-id pub-id-type="pmid">26771021</pub-id><pub-id pub-id-type="doi">10.1016/j.cels.2015.12.004</pub-id></element-citation></ref><ref id="R67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biol</source><year>2014</year><volume>15</volume><issue>12</issue><fpage>550</fpage><pub-id pub-id-type="pmcid">PMC4302049</pub-id><pub-id pub-id-type="pmid">25516281</pub-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id></element-citation></ref><ref id="R68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Riverol</surname><given-names>Y</given-names></name><name><surname>Bai</surname><given-names>J</given-names></name><name><surname>Bandla</surname><given-names>C</given-names></name><etal/></person-group><article-title>The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences</article-title><source>Nucleic Acids Res</source><year>2022</year><month>Jan</month><day>7</day><volume>50</volume><issue>D1</issue><fpage>D543</fpage><lpage>d552</lpage><pub-id pub-id-type="pmcid">PMC8728295</pub-id><pub-id pub-id-type="pmid">34723319</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkab1038</pub-id></element-citation></ref><ref id="R69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Austin</surname><given-names>KM</given-names></name><name><surname>Covic</surname><given-names>L</given-names></name><name><surname>Kuliopulos</surname><given-names>A</given-names></name></person-group><article-title>Matrix metalloproteases and PAR1 activation</article-title><source>Blood</source><year>2013</year><month>Jan</month><day>17</day><volume>121</volume><issue>3</issue><fpage>431</fpage><lpage>9</lpage><pub-id pub-id-type="pmcid">PMC3548166</pub-id><pub-id pub-id-type="pmid">23086754</pub-id><pub-id pub-id-type="doi">10.1182/blood-2012-09-355958</pub-id></element-citation></ref><ref id="R70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trivedi</surname><given-names>V</given-names></name><name><surname>Boire</surname><given-names>A</given-names></name><name><surname>Tchernychev</surname><given-names>B</given-names></name><etal/></person-group><article-title>Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site</article-title><source>Cell</source><year>2009</year><month>Apr</month><day>17</day><volume>137</volume><issue>2</issue><fpage>332</fpage><lpage>43</lpage><pub-id pub-id-type="pmcid">PMC2807741</pub-id><pub-id pub-id-type="pmid">19379698</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2009.02.018</pub-id></element-citation></ref><ref id="R71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mastenbroek</surname><given-names>TG</given-names></name><name><surname>Feijge</surname><given-names>MA</given-names></name><name><surname>Kremers</surname><given-names>RM</given-names></name><etal/></person-group><article-title>Platelet-Associated Matrix Metalloproteinases Regulate Thrombus Formation and Exert Local Collagenolytic Activity</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2015</year><month>Dec</month><volume>35</volume><issue>12</issue><fpage>2554</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">26471268</pub-id></element-citation></ref><ref id="R72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brinckerhoff</surname><given-names>CE</given-names></name><name><surname>Rutter</surname><given-names>JL</given-names></name><name><surname>Benbow</surname><given-names>U</given-names></name></person-group><article-title>Interstitial collagenases as markers of tumor progression</article-title><source>Clin Cancer Res</source><year>2000</year><month>Dec</month><volume>6</volume><issue>12</issue><fpage>4823</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">11156241</pub-id></element-citation></ref><ref id="R73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>CH</given-names></name><name><surname>Senfter</surname><given-names>D</given-names></name><name><surname>Basilio</surname><given-names>J</given-names></name><etal/></person-group><article-title>NF-kB contributes to MMP1 expression in breast cancer spheroids causing paracrine PAR1 activation and disintegrations in the lymph endothelial barrier in vitro</article-title><source>Oncotarget</source><year>2015</year><month>Nov</month><day>17</day><volume>6</volume><issue>36</issue><fpage>39262</fpage><lpage>75</lpage><pub-id pub-id-type="pmcid">PMC4770771</pub-id><pub-id pub-id-type="pmid">26513020</pub-id><pub-id pub-id-type="doi">10.18632/oncotarget.5741</pub-id></element-citation></ref><ref id="R74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boire</surname><given-names>A</given-names></name><name><surname>Covic</surname><given-names>L</given-names></name><name><surname>Agarwal</surname><given-names>A</given-names></name><name><surname>Jacques</surname><given-names>S</given-names></name><name><surname>Sherifi</surname><given-names>S</given-names></name><name><surname>Kuliopulos</surname><given-names>A</given-names></name></person-group><article-title>PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells</article-title><source>Cell</source><year>2005</year><month>Feb</month><day>11</day><volume>120</volume><issue>3</issue><fpage>303</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">15707890</pub-id></element-citation></ref><ref id="R75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arman</surname><given-names>M</given-names></name><name><surname>Krauel</surname><given-names>K</given-names></name></person-group><article-title>Human platelet IgG Fc receptor FcγRIIA in immunity and thrombosis</article-title><source>J Thromb Haemost</source><year>2015</year><month>Jun</month><volume>13</volume><issue>6</issue><fpage>893</fpage><lpage>908</lpage><pub-id pub-id-type="pmid">25900780</pub-id></element-citation></ref><ref id="R76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thienel</surname><given-names>M</given-names></name><name><surname>Müller-Reif</surname><given-names>JB</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Immobility-associated thromboprotection is conserved across mammalian species from bear to human</article-title><source>Science</source><year>2023</year><month>Apr</month><day>14</day><volume>380</volume><issue>6641</issue><fpage>178</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">37053338</pub-id></element-citation></ref><ref id="R77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaiser</surname><given-names>WJ</given-names></name><name><surname>Holbrook</surname><given-names>LM</given-names></name><name><surname>Tucker</surname><given-names>KL</given-names></name><name><surname>Stanley</surname><given-names>RG</given-names></name><name><surname>Gibbins</surname><given-names>JM</given-names></name></person-group><article-title>A functional proteomic method for the enrichment of peripheral membrane proteins reveals the collagen binding protein Hsp47 is exposed on the surface of activated human platelets</article-title><source>J Proteome Res</source><year>2009</year><month>Jun</month><volume>8</volume><issue>6</issue><fpage>2903</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">19341245</pub-id></element-citation></ref><ref id="R78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasikumar</surname><given-names>P</given-names></name><name><surname>AlOuda</surname><given-names>KS</given-names></name><name><surname>Kaiser</surname><given-names>WJ</given-names></name><etal/></person-group><article-title>The chaperone protein HSP47: a platelet collagen binding protein that contributes to thrombosis and hemostasis</article-title><source>J Thromb Haemost</source><year>2018</year><month>May</month><volume>16</volume><issue>5</issue><fpage>946</fpage><lpage>959</lpage><pub-id pub-id-type="pmcid">PMC6434988</pub-id><pub-id pub-id-type="pmid">29512284</pub-id><pub-id pub-id-type="doi">10.1111/jth.13998</pub-id></element-citation></ref><ref id="R79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giordano</surname><given-names>M</given-names></name><name><surname>Croci</surname><given-names>DO</given-names></name><name><surname>Rabinovich</surname><given-names>GA</given-names></name></person-group><article-title>Galectins in hematological malignancies</article-title><source>Curr Opin Hematol</source><year>2013</year><month>Jul</month><volume>20</volume><issue>4</issue><fpage>327</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">23695449</pub-id></element-citation></ref><ref id="R80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Colombo</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><etal/></person-group><article-title>A pro-inflammatory stem cell niche drives myelofibrosis through a targetable galectin 1 axis</article-title><source>bioRxiv</source><year>2023</year><elocation-id>2023.08.05.550630</elocation-id><pub-id pub-id-type="doi">10.1101/2023.08.05.550630</pub-id></element-citation></ref><ref id="R81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diklic</surname><given-names>M</given-names></name><name><surname>Mitrovic-Ajtic</surname><given-names>O</given-names></name><name><surname>Suboticki</surname><given-names>T</given-names></name><etal/></person-group><article-title>IL6 inhibition of inflammatory S100A8/9 proteins is NF-kB mediated in essential thrombocythemia</article-title><source>Cell Biochem Funct</source><year>2020</year><month>Jun</month><volume>38</volume><issue>4</issue><fpage>362</fpage><lpage>372</lpage><pub-id pub-id-type="pmid">31885098</pub-id></element-citation></ref><ref id="R82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leimkuhler</surname><given-names>NB</given-names></name><name><surname>Costa</surname><given-names>IG</given-names></name><name><surname>Schneider</surname><given-names>RK</given-names></name></person-group><article-title>From cell to cell: Identification of actionable targets in bone marrow fibrosis using single-cell technologies</article-title><source>Exp Hematol</source><year>2021</year><month>Dec</month><volume>104</volume><fpage>48</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">34601067</pub-id></element-citation></ref><ref id="R83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Jing</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name></person-group><article-title>S100A8/A9 in Inflammation</article-title><source>Front Immunol</source><year>2018</year><volume>9</volume><fpage>1298</fpage><pub-id pub-id-type="pmcid">PMC6004386</pub-id><pub-id pub-id-type="pmid">29942307</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.01298</pub-id></element-citation></ref><ref id="R84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>YH</given-names></name><name><surname>Chen</surname><given-names>YJ</given-names></name><name><surname>Lai</surname><given-names>YH</given-names></name><etal/></person-group><article-title>Mutation-Driven S100A8 Overexpression Confers Aberrant Phenotypes in Type 1 CALR-Mutated MPN</article-title><source>Int J Mol Sci</source><year>2023</year><month>May</month><day>14</day><volume>24</volume><issue>10</issue><pub-id pub-id-type="pmcid">PMC10217897</pub-id><pub-id pub-id-type="pmid">37240094</pub-id><pub-id pub-id-type="doi">10.3390/ijms24108747</pub-id></element-citation></ref><ref id="R85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kovacic</surname><given-names>M</given-names></name><name><surname>Mitrovic-Ajtic</surname><given-names>O</given-names></name><name><surname>Beleslin-Cokic</surname><given-names>B</given-names></name><etal/></person-group><article-title>TLR4 and RAGE conversely mediate pro-inflammatory S100A8/9-mediated inhibition of proliferation-linked signaling in myeloproliferative neoplasms</article-title><source>Cell Oncol (Dordr)</source><year>2018</year><month>Oct</month><volume>41</volume><issue>5</issue><fpage>541</fpage><lpage>553</lpage><pub-id pub-id-type="pmid">29946821</pub-id></element-citation></ref><ref id="R86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lay</surname><given-names>AJ</given-names></name><name><surname>Dupuy</surname><given-names>A</given-names></name><name><surname>Hagimola</surname><given-names>L</given-names></name><etal/></person-group><article-title>Endoplasmic reticulum protein 5 attenuates platelet endoplasmic reticulum stress and secretion in a mouse model</article-title><source>Blood Adv</source><year>2023</year><month>May</month><day>9</day><volume>7</volume><issue>9</issue><fpage>1650</fpage><lpage>1665</lpage><pub-id pub-id-type="pmcid">PMC10182305</pub-id><pub-id pub-id-type="pmid">36508284</pub-id><pub-id pub-id-type="doi">10.1182/bloodadvances.2022008457</pub-id></element-citation></ref><ref id="R87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Chiu</surname><given-names>J</given-names></name><name><surname>Scartelli</surname><given-names>C</given-names></name><etal/></person-group><article-title>Sulfenylation links oxidative stress to protein disulfide isomerase oxidase activity and thrombus formation</article-title><source>J Thromb Haemost</source><year>2023</year><month>Aug</month><volume>21</volume><issue>8</issue><fpage>2137</fpage><lpage>2150</lpage><pub-id pub-id-type="pmcid">PMC10657653</pub-id><pub-id pub-id-type="pmid">37037379</pub-id><pub-id pub-id-type="doi">10.1016/j.jtha.2023.03.034</pub-id></element-citation></ref><ref id="R88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>J</given-names></name><name><surname>Lordier</surname><given-names>L</given-names></name><name><surname>Meyran</surname><given-names>D</given-names></name><etal/></person-group><article-title>The formin DIAPH1 (mDia1) regulates megakaryocyte proplatelet formation by remodeling the actin and microtubule cytoskeletons</article-title><source>Blood</source><year>2014</year><month>Dec</month><day>18</day><volume>124</volume><issue>26</issue><fpage>3967</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">25298036</pub-id></element-citation></ref><ref id="R89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirakawa</surname><given-names>R</given-names></name><name><surname>Yoshioka</surname><given-names>A</given-names></name><name><surname>Horiuchi</surname><given-names>H</given-names></name><name><surname>Nishioka</surname><given-names>H</given-names></name><name><surname>Tabuchi</surname><given-names>A</given-names></name><name><surname>Kita</surname><given-names>T</given-names></name></person-group><article-title>Small GTPase Rab4 regulates Ca2+-induced alpha-granule secretion in platelets</article-title><source>J Biol Chem</source><year>2000</year><month>Oct</month><day>27</day><volume>275</volume><issue>43</issue><fpage>33844</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10938270</pub-id></element-citation></ref><ref id="R90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Quan</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name></person-group><article-title>CD63 negatively regulates hepatocellular carcinoma development through suppression of inflammatory cytokine-induced STAT3 activation</article-title><source>J Cell Mol Med</source><year>2021</year><month>Jan</month><volume>25</volume><issue>2</issue><fpage>1024</fpage><lpage>1034</lpage><pub-id pub-id-type="pmcid">PMC7812266</pub-id><pub-id pub-id-type="pmid">33277798</pub-id><pub-id pub-id-type="doi">10.1111/jcmm.16167</pub-id></element-citation></ref><ref id="R91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alam</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Up-regulated cathepsin C induces macrophage M1 polarization through FAK-triggered p38 MAPK/NF-kB pathway</article-title><source>Exp Cell Res</source><year>2019</year><month>Sep</month><day>15</day><volume>382</volume><issue>2</issue><elocation-id>111472</elocation-id><pub-id pub-id-type="pmid">31229505</pub-id></element-citation></ref><ref id="R92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joshi</surname><given-names>S</given-names></name><name><surname>Banerjee</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Alterations in platelet secretion differentially affect thrombosis and hemostasis</article-title><source>Blood Adv</source><year>2018</year><month>Sep</month><day>11</day><volume>2</volume><issue>17</issue><fpage>2187</fpage><lpage>2198</lpage><pub-id pub-id-type="pmcid">PMC6134224</pub-id><pub-id pub-id-type="pmid">30185436</pub-id><pub-id pub-id-type="doi">10.1182/bloodadvances.2018019166</pub-id></element-citation></ref><ref id="R93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Tan</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>EIF4G1 Is a Potential Prognostic Biomarker of Breast Cancer</article-title><source>Biomolecules</source><year>2022</year><month>Nov</month><day>26</day><volume>12</volume><issue>12</issue><pub-id pub-id-type="pmcid">PMC9776011</pub-id><pub-id pub-id-type="pmid">36551184</pub-id><pub-id pub-id-type="doi">10.3390/biom12121756</pub-id></element-citation></ref><ref id="R94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albakova</surname><given-names>Z</given-names></name><name><surname>Armeev</surname><given-names>GA</given-names></name><name><surname>Kanevskiy</surname><given-names>LM</given-names></name><name><surname>Kovalenko</surname><given-names>EI</given-names></name><name><surname>Sapozhnikov</surname><given-names>AM</given-names></name></person-group><article-title>HSP70 Multi-Functionality in Cancer</article-title><source>Cells</source><year>2020</year><month>Mar</month><day>2</day><volume>9</volume><issue>3</issue><pub-id pub-id-type="pmcid">PMC7140411</pub-id><pub-id pub-id-type="pmid">32121660</pub-id><pub-id pub-id-type="doi">10.3390/cells9030587</pub-id></element-citation></ref><ref id="R95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trepel</surname><given-names>J</given-names></name><name><surname>Mollapour</surname><given-names>M</given-names></name><name><surname>Giaccone</surname><given-names>G</given-names></name><name><surname>Neckers</surname><given-names>L</given-names></name></person-group><article-title>Targeting the dynamic HSP90 complex in cancer</article-title><source>Nat Rev Cancer</source><year>2010</year><month>Aug</month><volume>10</volume><issue>8</issue><fpage>537</fpage><lpage>49</lpage><pub-id pub-id-type="pmcid">PMC6778733</pub-id><pub-id pub-id-type="pmid">20651736</pub-id><pub-id pub-id-type="doi">10.1038/nrc2887</pub-id></element-citation></ref><ref id="R96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Targeting HSP90 as a Novel Therapy for Cancer: Mechanistic Insights and Translational Relevance</article-title><source>Cells</source><year>2022</year><month>Sep</month><day>6</day><volume>11</volume><issue>18</issue><pub-id pub-id-type="pmcid">PMC9497295</pub-id><pub-id pub-id-type="pmid">36139353</pub-id><pub-id pub-id-type="doi">10.3390/cells11182778</pub-id></element-citation></ref><ref id="R97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bennett</surname><given-names>JA</given-names></name><name><surname>Mastrangelo</surname><given-names>MA</given-names></name><name><surname>Ture</surname><given-names>SK</given-names></name><etal/></person-group><article-title>The choline transporter Slc44a2 controls platelet activation and thrombosis by regulating mitochondrial function</article-title><source>Nat Commun</source><year>2020</year><month>Jul</month><day>13</day><volume>11</volume><issue>1</issue><elocation-id>3479</elocation-id><pub-id pub-id-type="pmcid">PMC7359028</pub-id><pub-id pub-id-type="pmid">32661250</pub-id><pub-id pub-id-type="doi">10.1038/s41467-020-17254-w</pub-id></element-citation></ref><ref id="R98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Germain</surname><given-names>M</given-names></name><name><surname>Chasman</surname><given-names>DI</given-names></name><name><surname>de Haan</surname><given-names>H</given-names></name><etal/></person-group><article-title>Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism</article-title><source>Am J Hum Genet</source><year>2015</year><month>Apr</month><day>2</day><volume>96</volume><issue>4</issue><fpage>532</fpage><lpage>42</lpage><pub-id pub-id-type="pmcid">PMC4385184</pub-id><pub-id pub-id-type="pmid">25772935</pub-id><pub-id pub-id-type="doi">10.1016/j.ajhg.2015.01.019</pub-id></element-citation></ref><ref id="R99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ajanel</surname><given-names>A</given-names></name><name><surname>Campbell</surname><given-names>RA</given-names></name><name><surname>Denorme</surname><given-names>F</given-names></name></person-group><article-title>Platelet mitochondria: the mighty few</article-title><source>Curr Opin Hematol</source><year>2023</year><month>Sep</month><day>1</day><volume>30</volume><issue>5</issue><fpage>167</fpage><lpage>174</lpage><pub-id pub-id-type="pmcid">PMC10529105</pub-id><pub-id pub-id-type="pmid">37459354</pub-id><pub-id pub-id-type="doi">10.1097/MOH.0000000000000772</pub-id></element-citation></ref><ref id="R100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguilar</surname><given-names>A</given-names></name><name><surname>Weber</surname><given-names>J</given-names></name><name><surname>Boscher</surname><given-names>J</given-names></name><etal/></person-group><article-title>Combined deficiency of RAB32 and RAB38 in the mouse mimics Hermansky-Pudlak syndrome and critically impairs thrombosis</article-title><source>Blood Adv</source><year>2019</year><month>Aug</month><day>13</day><volume>3</volume><issue>15</issue><fpage>2368</fpage><lpage>2380</lpage><pub-id pub-id-type="pmcid">PMC6693013</pub-id><pub-id pub-id-type="pmid">31399401</pub-id><pub-id pub-id-type="doi">10.1182/bloodadvances.2019031286</pub-id></element-citation></ref><ref id="R101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osorio</surname><given-names>FG</given-names></name><name><surname>Soria-Valles</surname><given-names>C</given-names></name><name><surname>Santiago-Fernández</surname><given-names>O</given-names></name><etal/></person-group><article-title>Loss of the proteostasis factor AIRAPL causes myeloid transformation by deregulating IGF-1 signaling</article-title><source>Nat Med</source><year>2016</year><month>Jan</month><volume>22</volume><issue>1</issue><fpage>91</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">26692333</pub-id></element-citation></ref><ref id="R102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LaFave</surname><given-names>LM</given-names></name><name><surname>Levine</surname><given-names>RL</given-names></name></person-group><article-title>Targeting a regulator of protein homeostasis in myeloproliferative neoplasms</article-title><source>Nat Med</source><year>2016</year><month>Jan</month><volume>22</volume><issue>1</issue><fpage>20</fpage><lpage>1</lpage><pub-id pub-id-type="pmid">26735404</pub-id></element-citation></ref><ref id="R103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jutzi</surname><given-names>JS</given-names></name><name><surname>Marneth</surname><given-names>AE</given-names></name><name><surname>Jimenez-Santos</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>CALR-mutated cells are vulnerable to combined inhibition of the proteasome and the endoplasmic reticulum stress response</article-title><source>Leukemia</source><year>2023</year><month>Feb</month><volume>37</volume><issue>2</issue><fpage>359</fpage><lpage>369</lpage><pub-id pub-id-type="pmid">36473980</pub-id></element-citation></ref></ref-list></back><floats-group><boxed-text id="BX1" position="float" orientation="portrait"><caption><title>Highlights</title></caption><p>MPN patient platelet proteome identifies key pathobiological mediators of thrombosis and proteostasis.</p><p>The MPN platelet proteomic profile validates our prior findings from the platelet transcriptome.</p></boxed-text><fig id="F1" position="float"><label>Figure 1</label><caption><title>Patient variables representing MPN clinical cohort for proteomic work package.</title><p><bold>A,</bold> Similarity in distribution of MPN subtypes and controls, with slightly higher proportion ET (PV n= 41, ET n= 59, control n= 40) <bold>B</bold>, Comparable and balanced distribution of sex across MPN subtypes and controls. Larger percentage of female healthy controls. <bold>C,</bold> All patients with PV harbored the <italic>JAK2</italic> V617F mutation, and in keeping with the general ET population <italic>JAK2</italic> V617F was the most common driver mutation followed by <italic>CALR</italic> and <italic>MPL,</italic> with 12 triple negative ET patients included in this study<bold>. D,</bold> MPN patient therapies reflecting current clinical practice. The majority of PV and ET patients were prescribed aspirin (ASA), with hydroxyurea (HU) as a commonly utilized cytoreductive therapy. To control for any inter-patient variability, all treatment, in addition to patient, sex and experimental batch are adjusted as confounding factors in downstream differential expression analyses <bold>E,</bold> Comparable distribution of age across MPN subtypes and controls. Violin plots of patient age from each MPN subtype reflect clinical expectation, with slightly higher median age noted for ET and PV patients compared to controls. <bold>F,</bold> Platelet counts, as box plots, measured at the same date and time as experimental platelet sampling. As expected, Mann-Whitney <italic>U</italic> tests marked by asterisks indicate a statistically significant difference between control and MPN groups (*** <italic>p</italic>= &lt;0.001, ns = not significant).</p></caption><graphic xlink:href="EMS190173-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>MPN platelet proteome distinguishes disease phenotype and reveals subtype specific signatures.</title><p><bold>A,</bold> Unsupervised principal component analysis (PCA) of normalized platelet protein expression adjusted for age, sex, treatment (antiplatelet and cytoreduction) and experimental batch. PC1 and PC2 colored by MPN subtype; and each contrasted with controls (n= 40, yellow): ET (n= 59, ET (n= 59, light green), PV (n= 41, dark green). The first two principal components account for 26% of total variance in the data. <bold>B,</bold> Volcano plots (two panels of ET, PV) of differential protein expression showing log2 fold change versus statistical significance (negative log10 of <italic>p</italic>-values) of each gene. Significant up-regulated and down-regulated genes are those with <italic>p</italic>-values (FDR) smaller or equal to 0.05 and absolute value of fold changes larger or equal to 1.5.</p></caption><graphic xlink:href="EMS190173-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>The platelet proteome in MPN identifies biological pathways recognised as crucial drivers of disease.</title><p><bold>A,</bold> Pathway-enrichment analysis of proteins with MPN subtype-specific expression (color indicated; yellow ET, and light green PV). Each point represents a pathway; the <italic>x</italic>-axis gives the normalized enrichment score, which reflects the degree to which each pathway is over-represented at the top of the ranked list of differentially expressed proteins, normalized to account for differences in gene set size and in correlations between gene sets and the expression data set. The y-axis lists the detail-level node of the most enriched pathways; solid lines mark GSEA-recommended<sup><xref ref-type="bibr" rid="R65">65</xref></sup> Bonferroni-corrected statistical significance criterion of FDR &lt; 0.25 for exploratory analyses.</p></caption><graphic xlink:href="EMS190173-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><title>Correlation of differential expression between a shared set of significant genes and proteins.</title><p>Spearman’s correlation showed moderate (Rho = 0.44, <italic>p</italic> = 3.484e-11) correlation in differential expression (log2FC) of genes from the MPN platelet transcriptomic cohort that were also significantly differentially expressed (FDR &lt; 0.05) at the MPN platelet proteomic cohort.</p></caption><graphic xlink:href="EMS190173-f004"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><title>Highly expressed shared platelet proteo-transcriptome features in MPNs (A &amp; B)</title><p>Taking the overlap of the significantly differentially expressed proteins and genes (FDR &lt; 0.05) that were common across MPN subtypes (i.e., present in both ET and PV samples), we identified highly expressed features (n= 17) shared between the two independent cohorts. Hierarchically clustered heatmaps of the overlapping features between significantly expressed protein and genes (FDR &lt;0.05) from controls versus MPN (present in both PV and ET). <bold>A,</bold> Transcriptomic expression from the Stanford single center cohort (n= 78). <bold>B,</bold> Proteomic expression from the international, multi-center collaborative (Ireland &amp; Italy: n= 140). Colored annotation is provided to indicate MPN subtype, mutation status and sex. Rows indicate gradation in expression on a yellow (low) to orange (high) scale. Columns indicate sample type from controls, ET, and PV.</p></caption><graphic xlink:href="EMS190173-f005"/></fig><table-wrap-group id="T1" position="float" orientation="portrait"><label>Table 1</label><table-wrap id="T01" position="float" orientation="portrait"><label>Table 1A</label><caption><title>MPN patient characteristics recruited across two sites (Papa Giovanni XXIII Hospital, Bergamo, Italy and Mater Misericordiae University Hospital, Dublin, Ireland) for proteomic analysis.</title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="top"/><th align="left" valign="top">ET</th><th align="left" valign="top">PV</th><th align="left" valign="top">Control</th></tr></thead><tbody><tr><td align="left" valign="top"><bold>Subject Count, n</bold></td><td align="left" valign="top">59</td><td align="left" valign="top">41</td><td align="left" valign="top">40</td></tr><tr><td align="left" valign="top"><bold>Sample Count, n</bold></td><td align="left" valign="top">59</td><td align="left" valign="top">41</td><td align="left" valign="top">40</td></tr><tr><td align="left" valign="top"><bold>Median age, y (range)</bold></td><td align="left" valign="top">61 (32-86)</td><td align="left" valign="top">63 (38-83)</td><td align="left" valign="top">45 (24-61)</td></tr><tr><td align="left" valign="top"><bold>Female, n (%)</bold></td><td align="left" valign="top">32 (54)</td><td align="left" valign="top">22 (54)</td><td align="left" valign="top">24 (60)</td></tr><tr><td align="left" valign="top"><bold>Platelet count, median (25% quartile, 75% quartile)</bold></td><td align="left" valign="top">540 (422, 778)</td><td align="left" valign="top">465 (318, 638)</td><td align="left" valign="top">244 (220, 265)</td></tr><tr><td align="left" valign="top"><bold>MPN driver mutation, n (%)</bold></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">      <italic>JAK2</italic> V617F</td><td align="left" valign="top">26 (44)</td><td align="left" valign="top">41 (100)</td><td align="left" valign="top">0 (0)</td></tr><tr><td align="left" valign="top">      <italic>CALR</italic></td><td align="left" valign="top">18 (31)</td><td align="left" valign="top">0 (0)</td><td align="left" valign="top">0 (0)</td></tr><tr><td align="left" valign="top">      <italic>MPL</italic></td><td align="left" valign="top">2 (3)</td><td align="left" valign="top">0 (0)</td><td align="left" valign="top">0 (0)</td></tr><tr><td align="left" valign="top">      Triple Negative</td><td align="left" valign="top">12 (21)</td><td align="left" valign="top">0 (0)</td><td align="left" valign="top">0 (0)</td></tr><tr><td align="left" valign="top">      Missing</td><td align="left" valign="top">1 (1)</td><td align="left" valign="top">0 (0)</td><td align="left" valign="top">0 (0)</td></tr><tr><td align="left" valign="top"><bold>Therapy, n (%)</bold></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">      <bold>Aspirin &amp; hydroxyurea</bold></td><td align="left" valign="top">27 (46)</td><td align="left" valign="top">28 (68)</td><td align="left" valign="top">0 (0)</td></tr><tr><td align="left" valign="top">      Aspirin only</td><td align="left" valign="top">20 (34)4</td><td align="left" valign="top">12 (30)</td><td align="left" valign="top">0 (0)</td></tr><tr><td align="left" valign="top">      Hydroxyurea only</td><td align="left" valign="top">(7)</td><td align="left" valign="top">0 (0)</td><td align="left" valign="top">0 (0)</td></tr><tr><td align="left" valign="top">      JAK inhibitor</td><td align="left" valign="top">0 (0)</td><td align="left" valign="top">0 (0)</td><td align="left" valign="top">0 (0)</td></tr><tr><td align="left" valign="top">      No treatment</td><td align="left" valign="top">8 (13)</td><td align="left" valign="top">1 (2)</td><td align="left" valign="top">40 (100)</td></tr></tbody></table></table-wrap><table-wrap id="T02" position="float" orientation="portrait"><label>Table 1B</label><caption><p>MPN patient characteristics recruited at single center (Stanford, USA<sup><xref ref-type="bibr" rid="R21">21</xref></sup>) included here for comparative transcriptomic analysis. Key demographic and other patient variables (listed below) have no statistically significant difference (unpaired t-test) between the (transcriptome) and Mater/Bergamo proteome cohorts. These variables include: age, sex, platelet count, and distribution of MPN driver mutation (<italic>JAK2, CALR, MPL)</italic> and therapy (aspirin, hydroxyurea).</p></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="top"/><th align="left" valign="top">ET</th><th align="left" valign="top">PV</th><th align="left" valign="top">Control</th></tr></thead><tbody><tr><td align="left" valign="top"><bold>Subject Count, n</bold></td><td align="left" valign="top">24</td><td align="left" valign="top">31</td><td align="left" valign="top">21</td></tr><tr><td align="left" valign="top"><bold>Sample Count, n</bold></td><td align="left" valign="top">24</td><td align="left" valign="top">33</td><td align="left" valign="top">21</td></tr><tr><td align="left" valign="top"><bold>Median age, y (range)</bold></td><td align="left" valign="top">58 (30-78)</td><td align="left" valign="top">60 (27-84)</td><td align="left" valign="top">57 (26-69)</td></tr><tr><td align="left" valign="top"><bold>Female, n (%)</bold></td><td align="left" valign="top">16 (66)</td><td align="left" valign="top">14 (45)</td><td align="left" valign="top">5 (24)</td></tr><tr><td align="left" valign="top"><bold>Platelet count, median</bold></td><td align="left" valign="top">562</td><td align="left" valign="top">447 (310, 557)</td><td align="left" valign="top">167 (146,185)</td></tr><tr><td align="left" valign="top"><bold>(25% quartile, 75% quartile)</bold></td><td align="left" valign="top">(464,799)</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><bold>MPN driver mutation, n (%)</bold></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">       <italic>JAK2</italic> V617F</td><td align="left" valign="top">13 (54)</td><td align="left" valign="top">31 (100)</td><td align="left" valign="top">0 (0)</td></tr><tr><td align="left" valign="top">       <italic>CALR</italic></td><td align="left" valign="top">7 (30)</td><td align="left" valign="top">0 (0)</td><td align="left" valign="top">0 (0)</td></tr><tr><td align="left" valign="top">       <italic>MPL</italic></td><td align="left" valign="top">2 (8)</td><td align="left" valign="top">0 (0)</td><td align="left" valign="top">0 (0)</td></tr><tr><td align="left" valign="top">       Triple Negative</td><td align="left" valign="top">2 (8)</td><td align="left" valign="top">0 (0)</td><td align="left" valign="top">0 (0)</td></tr><tr><td align="left" valign="top">       Missing</td><td align="left" valign="top">0 (0)</td><td align="left" valign="top">0 (0)</td><td align="left" valign="top">0 (0)</td></tr><tr><td align="left" valign="top"><bold>Therapy, n (%)</bold></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><bold>Aspirin &amp; hydroxyurea</bold></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">       Aspirin only</td><td align="left" valign="top">6 (25)</td><td align="left" valign="top">10 (32)</td><td align="left" valign="top">0 (0)</td></tr><tr><td align="left" valign="top">       Hydroxyurea only</td><td align="left" valign="top">10 (42)</td><td align="left" valign="top">12 (39)</td><td align="left" valign="top">0 (0)</td></tr><tr><td align="left" valign="top">       JAK inhibitor</td><td align="left" valign="top">5 (21)</td><td align="left" valign="top">1 (3)</td><td align="left" valign="top">0 (0)</td></tr><tr><td align="left" valign="top">       No treatment</td><td align="left" valign="top">1 (4)</td><td align="left" valign="top">7 (23)</td><td align="left" valign="top">0 (0)</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">2(8)</td><td align="left" valign="top">3(9)</td><td align="left" valign="top">21 (100)</td></tr></tbody></table></table-wrap></table-wrap-group><table-wrap id="T2" position="float" orientation="portrait"><label>Table 2</label><caption><title>Select/representative candidate proteins that may variably influence the proinflammatory, pro-thrombotic, and profibrotic processes in MPNs.</title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="top">Candidate protein (Gene name)</th><th align="left" valign="top">Platelet differential expression by MPN subtype Absolute fold change (direction of change)</th><th align="left" valign="top">Cellular function and relationship to procoagulant, proinflammatory, and profibrotic pathways in other published work.</th></tr></thead><tbody><tr><td align="left" valign="top"><bold>MMP1</bold></td><td align="left" valign="top"><bold>PV:</bold> 4.5 (increased)<break/><bold>ET:</bold> 5.2 (increased)</td><td align="left" valign="top">MMP1, an interstitial collagenase, is known to cleave protease-activated receptor 1 (PAR1) and promote platelet activation and regulate thrombogenesis in vitro<sup><xref ref-type="bibr" rid="R69">69</xref>–<xref ref-type="bibr" rid="R71">71</xref></sup>. Furthermore, MMP1 mediates tumor invasion by compromising vascular barrier integrity and has been associated with inferior prognosis in solid organ malignancies<sup><xref ref-type="bibr" rid="R72">72</xref>–<xref ref-type="bibr" rid="R74">74</xref></sup>.</td></tr><tr><td align="left" valign="top"><bold>FcγRIIA</bold></td><td align="left" valign="top"><bold>PV:</bold> 2 (increased)<break/><bold>ET:</bold> 2 (increased)</td><td align="left" valign="top">Unbalanced FcγRIIA-mediated platelet aggregation was previously reported to promote thrombosis<sup><xref ref-type="bibr" rid="R75">75</xref></sup>.</td></tr><tr><td align="left" valign="top"><bold>SERPINH1</bold></td><td align="left" valign="top"><bold>PV:</bold> 2 (increased)</td><td align="left" valign="top">There is evidence of decreased expression or ablation of this collagen binding, platelet adhesion protein in immobilized mammals as a thromboprotective mechanism<sup><xref ref-type="bibr" rid="R76">76</xref>–<xref ref-type="bibr" rid="R78">78</xref></sup>.</td></tr><tr><td align="left" valign="top"><bold>LGALS1</bold></td><td align="left" valign="top"><bold>PV:</bold> 6.7 (increased)<break/><bold>ET:</bold> 4.7 (increased)</td><td align="left" valign="top">Galactin-1 is a beta-galactosidase binding protein which is reported to promote tumour cell proliferation and survival in haematological malignancies<sup><xref ref-type="bibr" rid="R79">79</xref></sup>. Recent data delineates the contribution of galactin-1 to disease severity in myelofibrosis and identified the protein as a potential drug target with disease modifying effects<sup><xref ref-type="bibr" rid="R80">80</xref></sup>.</td></tr><tr><td align="left" valign="top"><bold>S100A6</bold></td><td align="left" valign="top"><bold>ET:</bold> 2 (increased)</td><td align="left" valign="top">The S100 family of proteins is a major player in hematopoietic proliferation and recent work has identified proinflammatory/profibrotic roles for S100A6, S100A8, S100A9 in bone marrow, granulocytes, and plasma in MPN<sup><xref ref-type="bibr" rid="R80">80</xref>–<xref ref-type="bibr" rid="R85">85</xref></sup>.</td></tr><tr><td align="left" valign="top"><bold>PDIA6</bold></td><td align="left" valign="top"><bold>PV:</bold> 1.7 (increased)</td><td align="left" valign="top">Protein disulfide isomerases (PDIs) are key mediators of platelet ER homeostasis and the relationship between PDIs, ER &amp; oxidative stress, platelet activation and thrombosis has recently been elucidated<sup><xref ref-type="bibr" rid="R86">86</xref>,<xref ref-type="bibr" rid="R87">87</xref></sup>.</td></tr><tr><td align="left" valign="top"><bold>HPSE</bold></td><td align="left" valign="top"><bold>PV:</bold> 1.8 (increased)</td><td align="left" valign="top">Heparanase cleaves heparan sulfate proteoglycans and participates in extracellular matrix remodeling. It has been shown to be increased in the plasma extracellular vesicles of patients with PV<sup><xref ref-type="bibr" rid="R56">56</xref></sup>.</td></tr><tr><td align="left" valign="top"><bold>DIAPH1</bold></td><td align="left" valign="top"><bold>PV:</bold> 1.9 (increased)<break/><bold>ET:</bold> 1.8 (increased)</td><td align="left" valign="top">We find increased expression of protein diaphanous homolog-1 (DIAPH1) possibly suggesting altered megakaryopoiesis in peripherally circulating platelets in PV and ET. DIAPH regulates proplatelet formation via Rhomediated actin polymerization and microtubule assembly<sup><xref ref-type="bibr" rid="R88">88</xref></sup>.</td></tr><tr><td align="left" valign="top"><bold>RAB4A</bold></td><td align="left" valign="top"><bold>PV:</bold> 3.7 (increased)<break/><bold>ET:</bold> 2.3 (increased)</td><td align="left" valign="top">A Ras GTPase signaling protein which regulates platelet alpha granule release<sup><xref ref-type="bibr" rid="R89">89</xref></sup>.</td></tr><tr><td align="left" valign="top"><bold>CD63</bold></td><td align="left" valign="top"><bold>PV: 2.6</bold> (decreased)</td><td align="left" valign="top">Downregulation of CD63 has been associated with proliferation and metastasis in solid organ malignancy regulated by IL-6, IL-27 and STAT3 signaling<sup><xref ref-type="bibr" rid="R90">90</xref></sup>.</td></tr><tr><td align="left" valign="top"><bold>CTSC</bold></td><td align="left" valign="top"><bold>PV:</bold> 2 (increased)</td><td align="left" valign="top">Abundant Cathepsin C drives inflammation through macrophage activation via NF-κB signaling pathway<sup><xref ref-type="bibr" rid="R91">91</xref></sup>.</td></tr><tr><td align="left" valign="top"><bold>VAMP8</bold></td><td align="left" valign="top"><bold>ET:</bold> 1.7 (increased)</td><td align="left" valign="top">VAMP8 regulates platelet granule secretion and thrombosis <italic>in vivo<sup><xref ref-type="bibr" rid="R92">92</xref></sup>.</italic></td></tr><tr><td align="left" valign="top"><bold>EIF4G1</bold></td><td align="left" valign="top"><bold>PV:</bold> 2.1 (increased)<break/><bold>ET:</bold> 1.74 (increased)</td><td align="left" valign="top">EIF4G1 has been identified as a prognostic biomarker in breast cancer<sup><xref ref-type="bibr" rid="R93">93</xref></sup>.</td></tr><tr><td align="left" valign="top"><bold>HSP90AB1</bold></td><td align="left" valign="top"><bold>ET:</bold> 1.5 (increased)</td><td align="left" valign="top">We find increased expression of heat shock proteins in ET (HSP90AB1, TRAP1) and PV (HYOU1, HSPH1, DNAJA2). Heat shock protein 70 kDa and heat shock protein 90 kDa are two families of chaperone networks with integral roles in protein folding, degradation, trafficking, and maturation. They are known to promote oncogenesis by protecting a spectrum of cancer related proteins<sup><xref ref-type="bibr" rid="R94">94</xref>–<xref ref-type="bibr" rid="R96">96</xref></sup>.</td></tr><tr><td align="left" valign="top"><bold>SLC25A2</bold></td><td align="left" valign="top"><bold>PV:</bold> 1.9 (decreased)</td><td align="left" valign="top">SLC25A2 is decreased in PV (with SLC2A3 and SLC44A1 differentially expressed in ET). Solute membrane carrier proteins have been associated with venous thromboembolism in genome wide association studies and <italic>in vivo</italic> models<sup><xref ref-type="bibr" rid="R97">97</xref>,<xref ref-type="bibr" rid="R98">98</xref></sup>.</td></tr><tr><td align="left" valign="top"><bold>RAB32</bold></td><td align="left" valign="top"><bold>PV:</bold> 2.1 (increased)<break/><bold>ET:</bold> 1.6 (increased)</td><td align="left" valign="top">RAB32 is increased in ET (along with mitochondrial membrane protein TOMM22). Mitochondria are recognized as key regulators of platelet procoagulant function<sup><xref ref-type="bibr" rid="R99">99</xref></sup>. Loss of mitochondrial protein RAB32 is associated with dense granule storage pool disease Hermansky-Pudlak syndrome<sup><xref ref-type="bibr" rid="R100">100</xref></sup>.</td></tr><tr><td align="left" valign="top"><bold>PSMD11</bold></td><td align="left" valign="top"><bold>PV:</bold> 2 (increased)<break/><bold>ET:</bold> 1.7 (increased)</td><td align="left" valign="top">We show evidence of dysregulated protein degradation pathways with upregulation of PSMD11 along with differential expression of lysosomal proteins (SORT1 and ATP6V) and other proteasomal subunits. This reflects the work of other groups who have shown that protein qualitycontrol pathways may be important in the pathogenesis of MPN and other prothrombotic diseases and represent novel therapeutic targets<sup><xref ref-type="bibr" rid="R101">101</xref>–<xref ref-type="bibr" rid="R103">103</xref></sup>.</td></tr></tbody></table></table-wrap></floats-group></article>